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ABSTRACT
IS MACROLIDE AND BETA-LACTAM COMBINATION THERAPY ASSOCIATED
WITH IMPROVEMENT IN HOSPITALIZED PATIENTS WITH PNEUMONIA? AN
ASSESSMENT OF CONFOUNDING BY INDICATION
Evangeline Pierce
October 31, 2018
Pneumonia and influenza are one of the leading causes of infectious
disease-related deaths worldwide. Current guidelines for the treatment of
hospitalized patients with community acquired pneumonia (CAP) include empiric
antimicrobial therapy with a macrolide and a beta-lactam. There is little
consensus among studies as to which antimicrobial regimen is best. The
confusing results seen may very well be due to lack of assessment of
confounding by indication (CBI). This analysis was a secondary analysis from
Hospitalized Adults with Pneumococcal Pneumonia: Incidence Study (HAPPI).
The study participants were those in HAPPI who had received either macrolide
and beta-lactam combination therapy or fluoroquinolone mono-therapy within the
first 24 hours (n= 3141). The outcomes studied were early clinical stability (ECS)
and 30 day mortality. No statistically significant association was found between
macrolide and beta-lactam use and ECS using any of the methods used for
addressing confounding by indication, logistic regression, propensity score
!iv

matching, or instrumental variable analysis (Odds Ratio (OR): 0.908, 95%
Confidence Interval (CI): 0.780, 1.059; OR: 0.916, 95% CI:0.775, 1.083; OR:
1.551, 95% CI: 0.777, 3.091, respectively). The two methods addressing
measured confounding (logistic regression and propensity score matching) had
similar OR’s while the method addressing unmeasured confounding (instrumental
variable analysis) had a contradictory OR, even though the results were all non
significant. No statistically significant association was found between macrolide
and beta-lactam use and 30 day mortality using logistic regression, propensity
score matching, or instrumental variable analysis (OR: 0.926, 95% CI: 0.692,
1.241; OR: 0.885, 95% CI: 0.748, 1.048; OR: 0.958, 95% CI: 0.603, 1.523,
respectively). All three methods looking at combination therapy and 30 day
mortality were in agreement. When addressing confounding and CBI more than
one method for analysis should be used.
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LITERATURE REVIEW

1.1.1 Introduction

The purpose of this dissertation is to determine the efficacy of macrolide
and beta-lactam combination therapy versus fluoroquinolone mono-therapy in the
treatment of community acquired pneumonia (CAP) through the assessment of
early clinical stability (ECS) and 30 day mortality through the comparison of three
different statistical approaches to controlling for confounding by indication. Data
was extracted from the Hospitalized Adults with Pneumococcal Pneumonia:
Incidence Study (HAPPI). Currently, there is a lack of consensus among
epidemiological studies as to which antimicrobial regiment is best, due to
variation in the variables included and lack of using more than one statistical
method to address confounders and thus confounding by indication. There are
two specific aims for this dissertation. The first is to evaluate three years of study
data and determine whether macrolide and beta-lactam combination therapy
usage is appropriate for gold standard treatment in hospitalized community
acquired pneumonia though assessment of ECS and 30 day mortality. The
second aim is to assess and compare various methods addressing CBI
(multivariable logistic regression, propensity score stratification and matching,
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instrumental variable analysis) through the assessment of macrolide and betalactam combination therapy and its effect on ECS and 30 day mortality in
hospitalized patients with community acquired pneumonia.

1.1.2 Community Acquired Pneumonia
Together, pneumonia and influenza are leading causes of infectious
disease related deaths worldwide and the eighth leading cause of death in the
United States (1, 2). The setting in which pneumonia develops is important as it
determines the type of pneumonia: CAP, healthcare associated pneumonia
(HCAP), hospital-acquired pneumonia (HAP), or ventilator-associated
pneumonia (VAP) (3, 4). CAP is characterized by acute symptoms such as
dyspnea, cough, fever, or chest pain, and is diagnosed by the presence of
pulmonary infiltrate seen on radiography. It is distinguished from HAP in that the
patient is exposed to causative pathogens in the community and not a hospital
setting.
CAP is a common infectious disease with an estimated incidence of 2–11
cases per 1000 adults in the developed world and a mortality rate of 2%–14%
(5). It is approximated that, in the US, more than 1.5 million adults infected with
CAP are hospitalized annually, with 100,000 deaths occurring during
hospitalization (6, 7). Not only are the economic and clinical burdens of CAP
high, but there are also long term effects on quality of life that need to be
considered when looking at the overall effect of CAP (8).
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The risk of CAP increases with age: however those in early childhood are
also at increased risk (9, 10). It is estimated that 1 of every 20 persons aged 85
years or greater will have a new episode of CAP each year (10). Those with
increased age often have at least one other medical condition which can
complicate CAP (11). Elderly patients categorized as frail (i.e. those who need
help with daily activities, who have severe multimorbiditiy, polypharmacy, and
possible dementia) are at a much higher risk of CAP than those who have who
are not frail (11, 12). However, even without comorbidities, age is an independent
risk factor for CAP due to the decreased ability of the immune system to protect
against pathogens, decreased ability to have a productive cough, and decreased
swallowing reflex (13). CAP patients over 65 years of age account for about one
third of all cases, but they are also responsible for more than half of all
healthcare expenses (14). As the population of the US is aging, the burden of
CAP can only be expected to increase (15).
Many diseases and existing health conditions that can also cause greater
exposure or greater risk of exposure of heightened severity of CAP-causative
pathogens. Chronic lung diseases (i.e. cystic fibrosis, chronic obstructive
pulmonary disease (COPD), and lung cancer) that inhibit airflow can lead to
increased risk (16). Patients with Diabetes Mellitus, human immunodeficiency
virus (HIV), and those on immunosuppressants have increased risk of CAP due
to a compromised immune system (17, 18). Patients taking gastric acid
suppressants (medication that decreases the production of acid in the stomach),
those who smoke, and those who drink alcohol are at an increased risk for CAP
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(16, 19). A recent study also found that clusters of patients with CAP were found
in areas with low-income and black populations (7). Unlike many respiratory
diseases, CAP does not have seasonality (20).

1.1.3 Community Acquired Pneumonia: Etiology
CAP most common results from bacterial pathogens. However viruses,
fungi, and parasites are also known to cause CAP (21). Many causative CAP
pathogens are associated with specific risk factors. Risk factors for gramnegative bacilli include previous antibiotic therapy, recent hospitalization,
immunosuppression, pulmonary comorbidity (e.g., cystic fibrosis, bronchiectasis,
or repeated exacerbations of chronic obstructive pulmonary disease that require
frequent glucocorticoid and/or antibiotic use), probable aspiration, and multiple
medical comorbidities (eg, diabetes mellitus, alcoholism) (3, 22-24). Risk factors
associated with drug-resistant microbes include age over 65 years, beta-lactam,
macrolide, or fluoroquinolone therapy within the past three to six months,
alcoholism, medical comorbidities, immunosuppressive illness or therapy,
exposure to a child in a daycare center, prior hospitalization, or residence in a
long-term care facility (25).
Unfortunately the actual incidence is difficult to determine due to
contamination of samples with colonizing bacteria. S. pneumoniae has been
found in up to 15 percent of bacterial CAP cases, but the incidence of CAP due
to S. pneumoniae has been decreasing due to the use of pneumococcal
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vaccines in adults, as well as the decreasing prevalence of smoking (26, 27). S.
pneumoniae is the leading cause of pneumonia in the elderly population (28).
Other common bacteria known to cause CAP in adults are H. influenzae often
occurring in adults with underlying lung disease, M. pneumoniae the most
common CAP causing atypical bacteria, C. pneumoniae which is common in
outbreaks, Legionella which can occur sporadically or in outbreaks, and
Klebsiella pneumoniae which is common in those that have severe underlying
diseases such as alcoholism or diabetes (29-33).
The bacterial organisms are often split into two groups, typical and
atypical. Bacteria causing typical pneumonia include S. pneumoniae,
Haemophilus influenzae, Staphylococcus aureus, group A streptococci,
Moraxella catarrhalis, anaerobes, and aerobic gram-negative bacteria . Atypical
bacteria leading to atypical pneumonia include Legionella spp, M. pneumoniae,
C. pneumoniae, and Chlamydia psittaci.
The incidence of viral CAP depends on the diagnostic method used to
determine cause (34). The most common and significant virus is Influenza.
Infection with Influenza A or B can not only cause CAP, but it can also predispose
a patient to a superimposed bacterial infection which is causative for CAP (35).
Parainfluenza and respiratory syncytial virus (RSV) are seen more often in
immunocompromised adults; however, RSV can cause respiratory tract illnesses
in all age groups (36-38). Other viruses that have been found in patients with
CAP are rhinovirus, coronavirus, and human metapneumovirus. However, it is
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possible these viruses are not causative for CAP but simply predispose a person
to a bacterial co-infection (35).
Fungi are not a common cause of CAP, but they can cause CAP in both
immunocompetent and immunocompromised patients who live in or have visited
specific endemic areas. Coccidioides fungi are endemic to desert areas including
southern Arizona, central California, southwestern New Mexico, and west Texas,
and they have been found to cause CAP in patients from this area (39, 40). H.
capsulatum is most common in the Midwestern United States located in the Ohio
and Mississippi River Valleys; however the development of symptomatic disease
depends on the level of exposure (41, 42).
Determining the pathogenicity of CAP often depends on the severity of
CAP and the location of treatment, whether in the outpatient or inpatient setting
(3, 43). Many cases of CAP are never tested for a pathogen or have no pathogen
identified (30, 43). Traditionally, physicians consider lobar consolidation to be
due to the "typical" bacteria and interstitial infiltrates to be a result of
Pneumocystis jirovecii (formerly P. carinii) and viruses. Nevertheless, it has been
shown that radiologists cannot reliably differentiate bacterial from nonbacterial
pneumonia on the basis of a radiographic image (44, 45). Recently a review of
Medicare patients hospitalized for CAP in 2009 showed a microbial diagnosis
was made in less than 10% of cases (46). Blood cultures, sputum Gram stain
and cultures, and urine antigen tests are recommended in hospitalized patients
to determine the microbial diagnosis (3, 47).
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Blood cultures are positive for a pathogen in only 7 to 16 percent of
hospitalized patients with S. pneumoniae accounting for two-thirds of the positive
results (48, 49). There is a high rate of false positives with blood cultures (10%)
and in clinical practice a positive culture rarely leads to changes in antibiotic
therapy (48, 50).
Expectorated sputum can be used for testing via a Gram stain and culture,
though expectorated sputum can lead to contamination with upper airway flora.
Therefore other methods can be used such as transtracheal aspiration,
transthoracic aspiration, and the collection of specimens at bronchoscopy (46).
The sensitivity and specificity of the sputum Gram stain can vary in different
settings, with a meta analysis showing sensitivity of Gram stain compared with
culture ranging from 15 to 100 percent and specificity ranging from 11 to 100
percent (51). This variation is most likely from using different thresholds for a
positive test. Guidelines recommend that expectorated sputum Gram stain and
culture be done only if a good-quality sputum can be obtained (3).
Urinary antigen assays are typically used to detect S. pneumoniae and
Legionella. In a prospective study, the sensitivity of the pneumococcal urinary
antigen was 71 percent and the specificity was 96 percent. Interestingly the
results of the urinary antigen test led the clinicians in the study to reduce the
spectrum of antibiotics in nine percent of patients with CAP (52). It is
recommended that the pneumococcal urinary antigen assay be used to augment
the standard diagnostic methods of blood culture and sputum Gram stain and
culture (53). A new test that has been approved by the US Food and Drug
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Administration (FDA) is a polymerase chain reaction (PCR) for detecting C.
pneumoniae, M. pneumoniae, and 14 respiratory tract viruses, and these tests
are rapid, sensitive, and specific (54).

1.1.4 Community Acquired Pneumonia: Severity
CAP can be treated inpatient or outpatient. Severity of illness is the
strongest factor in the determination of location of treatment, but other factors
may taken into account, such as ability to maintain oral intake of fluids and
medications, likelihood of medication adherence, history of active substance
abuse, mental illness, cognitive or functional impairment, and living or social
circumstances (55).
The severity of CAP is oftentimes determined through the Pneumonia
Severity Index (PSI) (56). This score is used to predict the need for
hospitalization for a patient. PSI ranges from I to V, with a higher score indicating
much more severe CAP. The score includes demographic information,
comorbidities, initial physical exam results, lab results, and radiographical results
(56). PSI scores have low sensitivity and specificity for intensive care unit (ICU)
admission, and they do not account for other variables affecting severity such as
psychosocial variables, non-common comorbidities, or patient preferences
regarding treatment (11).
Another method to determine CAP severity is through CURB-65 scoring
(Confusion, Urea nitrogen, Respiratory rate, Blood pressure, 65 years of age and
!8

older) (57). CURB-65 scores, ranging from 0 to 5 with the severity of CAP
increasing with the score, are easier than the PSI to calculate and interpret as
CURB-65 includes only five variables compared to the possible 20 in the PSI.
The CRB-65 score provides a four-variable substitute for use where blood testing
is not available. The CURB-65 scores do not include data such as hypoxemia,
electrolyte disturbance or the inability to take oral medications which could
indicate greater severity of CAP (11).
Guidelines are not consistent in the recommendation of which score to
use for the determination of severity. The American Academy of Family
Physicians (AAFP) guidelines recommend outpatient treatment for PSI risk
classes I and II and hospitalization for those in risk classes IV and V. The location
of treatment for class III is left to clinical judgement (55, 58). The Infectious
Diseases Society of America (IDSA) guideline recommends that physicians
consider outpatient treatment for patients in PSI risk classes I, II and III, and
hospitalization for those in classes IV and V (3). The British Thoracic Society
(BTS) recommends that physicians use the CURB-65 or the CRB-65 when
deciding on hospitalization or outpatient treatment, with scores 0-1 being
recommended for outpatient treatment and 2-5 recommended for hospitalization.
(59). The American Thoracic Society (ATS) guidelines recommend that clinicians
use clinical decision scores like the PSI or CURB-65 to support clinical judgment,
but the do not define a recommended cutoff for hospital admission (60). Most
importantly all of the guidelines recommend that clinicians use PSI and CURB-65
scoring tools to support, not replace, clinical judgment.
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1.1.5.1 Community Acquired Pneumonia: Treatment
Treatment recommendations depend on the type of care a patient
requires. Once a patient meets the symptom requirements of CAP the necessary
level of care is decided. More severe cases will lead to an inpatient setting, which
occurs on medical wards or the ICU. Effective empirical treatment involves the
selection of an antimicrobial agent with a spectrum of activity that includes the
causative pathogen. Often, the causative organism takes a while to be confirmed
or is unable to be determined. Therefore empiric antimicrobial therapy is
encouraged to begin as soon as possible beginning with a broad-spectrum
antimicrobial agent before de-escalating to narrow-spectrum agents dependent
on the identification of a pathogen (3, 59, 61-63). It is recommend that
antimicrobials be administered as soon as possible after diagnosis of CAP and
before leaving the emergency department, especially in those over 65 years of
age (3, 64, 65). Patients with sepsis or septic shock should have antibiotics
started within one hour.

1.1.5.2 Community Acquired Pneumonia Treatment: Macrolides
Macrolide antimicrobials are used to treat gram-positive bacteria, such as
S. pneumoniae, and some gram-negative bacteria like H. influenzae. Macrolides
inhibit protein synthesis in bacteria by binding to the 50S ribosomal subunit and
preventing polypeptide elongation and thus protein synthesis (66, 67).
!10

Macrolides also appear to decrease the production of pro-inflammatory
cytokines, thereby decreasing inflammation in patients (68, 69). A study
assessed the affects of macrolides on the human immune system, ex vivo, using
healthy volunteers (70). It was found that there was a neutrophil degranulating
effect of azithromycin (a type of macrolide), which was seen in rapid decreases in
azurophilic granule enzyme activity in the cells, with corresponding increases in
the serum. The oxidative burst response to a particulate stimulus was also
enhanced. Both of these inflammatory responses occurred when serum and
neutrophil azithromycin concentrations were higher, peaking at the 24-hour mark
and then gradually decreasing over the next 27 days. In addition, decreases in
chemokines (IL-8 and human growth related oncogene-a) and IL-6 serum
concentrations accompanied a down-regulation of the oxidative burst and an
increase in neutrophil apoptosis for up to 28 days after. The fact that these antiinflammatory effects begin to occur so quickly after the start of a treatment
regimen could, in theory, correlate with the improved outcomes noted in some
CAP patients (69). It has also been suggested that macrolides can assist in the
stabilization of the epithelial membrane which contributes to decreased an
inflammation (67).
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1.1.5.3 Community Acquired Pneumonia Treatment: Beta-Lactam and Macrolides
Beta-lactams are antimicrobials that are effective against gram-positive
bacteria and some gram-negative bacteria. They act by inhibiting the synthesis of
bacterial walls (71).
In hospitalized patients with CAP empiric therapy with both a macrolide
and a beta-lactam is the preferred treatment according to the IDSA (3). Although
the mechanism of action is not well understood, it has been suggested that the
combination of a macrolide and a beta-lactam can lead to improved clinical
outcomes, including lower mortality (72, 73).

1.1.5.5 Community Acquired Pneumonia Treatment: Fluoroquinolone
Fluoroquinolones are direct inhibitors of bacterial DNA synthesis and bind
to the complex of specific enzymes within DNA, thus inhibiting progress of the
DNA replication, leading to bacterial DNA and cell death (74). Fluoroquinolones
work best against aerobic gram-negative bacilli (75). They are contraindicated if a
patient has significant QT prolongation, pre-existing CNS lesions or CNS
inflammation, or has suffered a stroke (76). Because of the severity of adverse
effects and the increased risk for C. difficile infection, combination therapy with a
beta-lactam plus a macrolide is recommended over mono-therapy with a
fluoroquinolone (3, 77). However, fluoroquinolones are an option for treating
atypical bacterial pneumonia (3).
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1.1.5.6 Community Acquired Pneumonia Treatment: Other Treatments
Antiviral therapy for non-influenza pneumonia has typically been evaluated
in immunosuppressed patients and infants. There has been minimal research
looking at the use of antivirals for other populations (78-82). Fungal CAP is
typically treated with an antifungal like Amphotericin B (or its derivatives) and
itraconazole (83).

1.1.5.7 Community Acquired Pneumonia Treatment: Recommendations
The current recommended first line antimicrobial treatment includes a
macrolide plus a beta-lactam (3). Respiratory fluoroquinolones are used in
patients who cannot take a macrolide or a beta-lactam (84). Strains of drug
resistant S. pneumoniae bring the current recommendations into question (85).
Even though the guidelines are widely accepted, there is disagreement on
the utility of macrolides in the treatment of CAP. The majority of the studies used
by the IDSA and the ATS were retrospective cohort studies (3). However, other
retrospective studies and some randomized control trials have given evidence to
question the benefits of macrolide as they suggest the use of beta-lactam monotherapy for patients hospitalized with mild CAP (86-93).
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1.1.6 Community Acquired Pneumonia: Clinical Outcomes
One way to measure how a patient with CAP is improving in the hospital is
to assess clinical stability. In a recent Federal Drug Administration (FDA) paper,
emphasis was placed on symptom resolution as objective evidence of clinical
improvement in patients with CAP (94). The FDA has also advocated for clinical
stability to be an important endpoint in clinical trials comparing different treatment
regimens (95). It has been found that the rate of mortality or readmission among
patients who had CAP was about 10% when a patient satisfied all conditions of
clinical stability (96).
The ATS has a defined set of criteria and guidelines as to what qualifies as
clinically stable (97). These criteria include improved symptoms of pneumonia
(cough and shortness of breath), lack of fever for at least eight hours, and
improving leukocytosis (white blood count decreased at least 10% from the
previous day). All of the ATS criteria should be present during the same day
compared to the previous day to define clinical stability. The IDSA has another
set of criteria for clinical stability (97). The criteria is listed as follows: temperature
</= 37.8 C, heart rate </= 100 beats per minute, respiratory rate </= 24 breaths
per minute, systolic blood pressure >/= 90 mmHg, arterial oxygen saturation >/=
90% or a partial pressure of oxygen >/= 60 mmHg on room air, and normal
mental status. The IDSA criteria should all be present on the same day to qualify
as clinically stable. Although the two set of criteria vary, it has been shown that
they are clinically equivalent and either can be used for research or clinical
practice (97).
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ECS occurs when the criteria are met on or before the third day of
hospitalization (98). ECS at day three was traditionally based on older studies
suggesting that clinical differences in patients treated with antibiotics are
apparent earlier than day three of antibiotic treatment. This same time frame is
also relevant because the results of the many pathogen tests are usually
available within three days (98-100).
Other outcomes typically studied with respect to CAP include in-hospital
mortality, 30-day mortality, long-term mortality, and readmission for CAP (3, 56,
101-105). Readmission to the hospital after discharge is typically used as an
indicator of vulnerability (106).

1.2.1 Community Acquired Pneumonia and Confounding by Indication
The pathogens and management of CAP have been well studied and
many of these studies have assessed antibiotic use for patients with CAP.
However these results can be brought into question when assessing for
confounding by indication (CBI) (87, 89, 107-115).
Confounding is present when a variable influences both the independent
variable (e.g. an antibiotic treatment) and the dependent variable (e.g. a clinical
outcome) (116). Confounding by indication (CBI) is a type of confounding that
occurs when a treatment (the primary predictor variable) is selected due to a
specific characteristic (e.g. history of a particular disease, provider medication
preference) and this characteristic also affects the risk of the outcome variable
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(117, 118). Not correctly addressing confounding can lead to biased and
inaccurate statistical results (117, 119).

1.2.3 Meta Analyses Assessing Antibiotic Usage in Community Acquired
Pneumonia
Meta-analyses have been performed to assess the effect of macrolide
therapy (both combination and mono therapy) on mortality associated with CAP,
Table 1 (88, 120).
Asadi et al, 2012, assessed macrolide based regimens (macrolide monotherapy, macrolide + beta lactam combination therapy, and fluoroquinolone
therapy) and mortality in hospitalized patients with CAP (88). They included both
randomized control trials and observational studies in their analysis, for a total of
23 studies, 18 observational cohorts and 5 randomized control trials. They found
macrolide use was associated with a statistically significant lower risk of mortality
compared with non-macrolide use (RR, 0.78; 95% CI, 0.64–0.95; P = .01). There
was a significant amount of heterogeneity among the studies (I2 = 85%) that was
not explained, though it could have been due to confounding by indication that
was not addressed equally across studies (i.e. it was noted that confounders
were not consistent throughout studies). Heterogeneity could have also resulted
from study design differences (e.g. low sample size, differences in inclusion or
exclusion criteria, etc.). This seems to be supported when one looks at the
effects of macrolide usage on mortality in only the randomized control trials
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(comparing macrolide-based regimens and fluoroquinolone treatment, RR, 1.13;
95% CI, 0.65–1.98; P = .66), where the heterogeneity was low (I2 = 0%). The
analysis also found that there was no significant difference of mortality comparing
macrolide and beta-lactam combinations and fluoroquinolone use (RR, 1.17;
95% CI, 0.91–1.50; P = .22; I2 = 43%). They concluded that treatment with a
macrolide regiment has a reduction in mortality compared to non-macrolide
treatments. However, no difference in mortality between macrolide and betalactam combination therapy and fluoroquinolone mono-therapy (both guideline
concordant treatments) was seen.
Vardakas et al, 2017, assessed mono-therapy (macrolides, beta-lactams,
and fluoroquinolones) and combination therapy (macrolide + beta-lactam,
fluoroquinolone + beta-lactam) in community-acquired pneumonia (120). Monotherapy regimens were not associated with higher mortality when compared with
combination therapies (RR 1.14, 95% CI 0.99-1.32, I2 84%). As seen with Asadi
et al, 2012, heterogeneity was lower or non existent in analyses of randomized
control trials.They propose that the percentage of patients with heart disease,
cancer and severe pneumonia could partly account for the observed
heterogeneity, but data for potential confounding factors were not consistently
reported across studies. Interestingly, macrolide mono-therapy was associated
with lower mortality than macrolide and beta-lactam combination therapy (0.68,
0.51-0.92, I2 32%), even after removing the two largest studies (0.59, 0.35-1.00,
I2 34%). The authors note that the lower mortality seen with macrolide monotherapy seems to contradict the increasing prevalence of resistance to macrolide
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antibiotics, unless there is an assumption that confounding by indication is
occurring, as seen in several of the included studies where macrolide monotherapy was administered in younger patients and those at a lower risk for death.
The authors conclude that this analysis of studies is not conclusive due to the
heterogeneity and lack of adjustment for confounding factors.

Table 1. Macrolide and CAP Meta Analyses
Study

Studies Assessed

Therapies Assessed

Results

Asadi et al, 23, included
2012
observational ans
randomized
control trials

Macrolide mono-therapy,
macrolide + beta-lactam
combination therapy,
fluoroquinolone monotherapy

Macrolide regiment has reduction
in mortality compared to nonmacrolide treatments. No
difference in mortality between
macrolide + beta-lactam
combination therapy and
fluoroquinolone mono-therapy

Vardakas
et al, 2017

Macrolide mono-therapy,
beta-lactam monotherapy, fluoroquinolone
mono-therapy, macrolide
+ beta-lactam
combination therapy,
fluoroquinolone + betalactam combination
therapy

Mono-therapy was not associated
with higher mortality than
combination therapy in North
American and retrospective
studies. No difference in mortality
between fluoroquinolone monotherapy and beta-lactam +
macrolide combination

50, included
observational and
randomized
control trials

1.2.4 Randomized Control Trials Assessing Antibiotic Usage in Community
Acquired Pneumonia
Randomized control trials are considered the gold standard when
evaluating the efficacy of treatments in clinical research. The randomization
inherent in this type of study means that when there are observed differences
between the treatment types with respect to a particular outcome variable, these
differences are due solely to the treatment and not to other variables (e.g. age,
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sex, other medications) (121). Randomized control trials also have minimal bias
and confounding variables (121). However, not only are randomized control trials
expensive, but they are sometimes unethical. As many patients hospitalized with
CAP are in critical condition, getting informed consent so the patient can
participate in a trial is sometimes impossible (i.e. the medication must be
administered immediately and patients are unable to consent).
Even with the complications that come with a randomized control trial,
there have been trials assessing the effectiveness of the recommended
macrolide and beta-lactam combination therapy against mono-therapy of nonmacrolide regimens, Table 3.
Garin et al, 2014, assessed the guideline treatment of macrolide and betalactam combination therapy against beta-lactam mono-therapy in a randomized
non-inferiority trial, which tests whether the treatment being evaluated is equally
as effective as the standard treatment (90). This was an open-label, multicenter,
non-inferiority, randomized trial in immunocompetent patients hospitalized with
CAP in Switzerland. Patients were treated with a beta-lactam and a macrolide
combination therapy or with beta-lactam mono-therapy. It was found after 7 days
of treatment, 41.2% of patients receiving combination therapy had not reached
clinical stability, compared to only 33.6% of patients receiving mono-therapy
(P=0.07). Interestingly, those who were known to have atypical pathogens or had
more severe pneumonia (PSI IV) were less likely to reach clinical stability at 7
days with the beta-lactam mono-therapy (HR, 0.99; 95% CI, 0.80-1.22). There
were more 30-day readmissions with beta-lactam mono-therapy (7.9%, P = .01).
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Additionally, there was no difference between combination therapy and monotherapy with respect to mortality, intensive care unit admission, complications,
length of stay, and recurrence of pneumonia within 90 days.
Postma et al, 2015, did a cluster-randomized, crossover trial assessing
patient outcomes in patients in the Netherlands who received guideline
concordant treatment, beta-lactam and macrolide combination therapy or
fluoroquinolone mono-therapy, and beta-lactam mono-therapy (122). In the
intention-to-treat analysis, the risk of death was higher by 1.9% (90% CI, -0.6 to
4.4) with the beta-lactam and macrolide combination therapy when compared to
the beta-lactam mono-therapy. The risk of death was lower by 0.6% (90% CI,
-2.8 to 1.9) with fluoroquinolone mono-therapy than with beta-lactam monotherapy. The study concluded that in patients with clinically suspected CAP
admitted to non-ICU wards, beta-lactam mono-therapy was non-inferior to betalactam and macrolide combination therapy or fluoroquinolone mono-therapy with
regard to 90-day mortality.
Figueiredo-Mell et al, 2018 assessed the effects of beta-lactam monotherapy versus beta-lactam and macrolide combination therapy in patients with
HIV and CAP (123). Based in Brazil, patients were given either a beta-lactam
and a placebo or a beta-lactam and a macrolide. There was no difference found
for in-patient mortality or 14-day mortality between the two groups, Hazard Ratio
(HR) 1.22, 95% CI 0.57-2.59 and RR 2.38, 95% CI 0.87-6.53, respectively.
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The results of these randomized trials bring into question the current
guideline recommendation of macrolide combination therapy (3).
Table 2. Randomized Control Trials and CAP Therapy
Study

Study Type

Therapies Assessed

Results

Garin et al,
2014

Randomized
noninferiority
trial

Beta-lactam monotherapy, macrolide +
beta-lactam combination
therapy

Noninferiority of beta-lactam
mono-therapy in patients
hospitalized for moderately severe
CAP was not found. Patients
infected with atypical pathogens or
with PSI category IV pneumonia
had delayed clinical stability with
mono-therapy.

Postma et
al, 2015

Clusterrandomized,
crossover trial

Beta-lactam monotherapy, macrolide +
beta-lactam combination
therapy, fluoroquinolone
mono-therapy

Paitents with clinically suspected
CAP admitted to non-ICU wards,
beta-lactam mono-therapy was
noninferior to beta-lactam and
macrolide combination therapy or
fluoroquinolone mono-therapy with
regard to 90-day mortality.

FigueiredoMell et al,
2018

Randomized
control trial

Beta-lactam monotherapy, macrolide +
beta-lactam combination
therapy

There was no difference in patient
outcomes in hospitalized patients
with HIV/AIDS with CAP, when
comparing bera-lactam monotherapy and macrolide plus betalactam combination therapy

1.2.5 Individual Studies Assessing Antibiotic Usage in Community Acquired
Pneumonia
Table 2 is an overview of many of the studies that have assessed
variations of antibiotic therapy and their effect on CAP (86, 87, 89, 109-114).
These studies were selected based on study location (in the United States) and
population age (non-pediatric). Some of these studies adjusted for CBI though
multivariable logistic regression, but those studies did not have a consensus on
the appropriate therapy for CAP (110, 112-114). Of note, logistic regression does
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not entirely control for CBI as many times the effects of the variables used are
often not truly independent of other individuals variables (124). Only one study
used a secondary method to control for CBI through propensity score analysis.
No difference in 30-day mortality in either beta-lactam and fluoroquinolone or
beta-lactam and macrolide combination therapies was found (89). Note that there
was no consensus between these studies regarding the effect of macrolide
usage on CAP, and the lack of overall assessment or attention to CBI brings
many of their conclusions into question.

Table 3. Macrolide Studies Assessing Confounding By Indication (CBI)
Study

Study Type

Antibiotic Assessed

Bratzler
et al,
2008

Retrospective Macrolide and
Cohort
Cephalosporin,
Quinolone

Yes, multivariable Cephalosporin and
logistic
macrolide combination
regression
therapy was associated
with decreased in hospital
mortality (AOR, 0.6; 95%
CI, 0.3–0.9; P p .018)

Frei et al,
2006

Retrospective Fluoroquinolone,
Cohort
Beta-lactam and
Macrolide

No

Lodise et
al , 2007

Retrospective Fluoroquinolone,
Cohort
Beta-lactam and
Macrolide

Yes, multivariable PSI class V patients had
logistic
lower 14-day and 30-day
regression
mortality rates with betalactam and macrolide than
with fluoroquinolone, (14day [P = 0.02]; 30-day [P
= 0.05]).

Wilson et
al, 2012

Retrospective Fluoroquinolone
Cohort
and Beta-lactam,
Macrolide and
Beta-lactam

Yes - multilevel
regression
models,
propensity score
analysis
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CBI Addressed

Results

Fluoroquinolone therapy
was associated with a
significantly shorter time
to switch therapy than
combination therapy (P =
0.01).

No significant difference in
30-day mortality between
those with a beta-lactam
and a fluoroquinolone vs
those with a beta-lactam
and a macrolide.

Table 3 continued. Macrolide Studies Assessing Confounding By Indication (CBI)
Study

Study Type

Asadi et
al , 2013

Antibiotic Assessed

CBI Addressed

Results

Retrospective Fluoroquinolone,
Cohort
Macrolide and
Beta-lactam

Yes Multivariable
logistic
regression

Macrolide and a betalactam were associated
with increased odds of
death or ICU admission vs
fluoroquinolone monotherapy (17.4% vs. 14.4%;
aOR, 1.58; 95% CI,
1.09-2.27; p 0.01).

Burgess
et al,
2000

Retrospective Macrolide and
Cohort
Cephalosporin,
Cephalosporin

No

There were no statistical
differences between
patients who had
cephalosporin monotherapy or combination
therapy in mortality (0.9%
vs 3.1%, respectively; P =
0.333)

Gleason
et al,
1999

Retrospective Macrolides and 2nd No
Cohort
generation
Cephalosporins,
Macrolides and 3nd
generation
Cephalosporins,
Macrolides and
Beta-lactams,
Fluoroquinolones,

Treatment with a 2nd
generation cephalosporin
plus macrolide (hazard
ratio [HR], 0.71; 95%
confidence interval [CI],
0.52-0.96), a 3rd
cephalosporin plus
macrolide (HR, 0.74; 95%
CI, 0.60-0.92), or
fluoroquinolone monotherapy (HR, 0.64; 95%
CI, 0.43-0.94) was
independently associated
with lower 30-day
mortality. Use of a betalactam plus macrolide
(HR, 1.77; 95% CI,
1.28-2.46) were
associated with an
increased 30-day mortality

Houck et
al, 2001

Retrospective Macrolides,
Cohort
Fluoroquinolones,
Beta-lactam,
Macrolide and
Beta-lactam

In 1995 lower mortality
was associated with
macrolide mono-therapy
(AOR, 0.24; 95% CI, 0.06
to 0.93). In 1997 lower
mortality was associated
with fluoroquinolone
mono-therapy compared
with beta-lactam monotherapy(AOR, 0.27; 95%
CI, 0.07 to 0.96).

Yes - logistic
regression
models
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Table 3 continued. Macrolide Studies Assessing Confounding By Indication (CBI)
Study

Study Type

Antibiotic Assessed

Mufson et Retrospective Macrolide and
al, 2006
Cohort
Cephalosporin,
Macrolide and
Beta-lactam, Betalactam

CBI Addressed

Results

No

Compared with betalactam mono-therapy,
combination macrolide
plus additional antibiotic
therapy effectively
lowered the case-fatality
rate among ill adults ⩾50
years of age.

1.3.1 Confounding By Indication
In an observational study, there is a predictor variable, which is the main
variable of interest in the study, and an outcome variable, the endpoint of interest
in a study. Confounding can appear to strengthen, weaken, or change the effect
of a primary predictor variable and the outcome (Figure 1).
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Figure 1. Diagram of Confounding

Three criteria must be met for a variable to be considered a confounder
(125, 126). One, a confounder must be an independent risk factor for the
outcome. Two, a confounder must be associated with the exposure. Three, a
confounder cannot be an intermediate variable between the exposure and the
outcome. Confounding variables can be measured or unmeasured (Figure 2).
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Figure 2. Diagram of Confounding, Measured (M) and Unmeasured (U)

CBI occurs when a specific treatment (primary predictor variable) is
selected for a particular characteristic and this characteristic also affects the risk
of the outcome variable. CBI is based on confounding bias, which can be
described as the differential distribution of a third factor between study groups
(127). For example, an investigator may be looking at the effect of antidepressants in pregnancy and its affect on the development of autism.
Depression would be a variable leading to CBI as it would indicate the need for
the treatment (via antidepressants) and it can also affect the development of
autism in a child, thereby affecting the risk of the outcome (128).
Due to the varying effects CBI can have between the primary predictor
variable and the outcome variable, it is important to control for this event through
various statistical means. Traditionally, the use of multivariable regression models
and propensity score methods are used, but a third lesser known method,
instrumental variable analysis is also effective in controlling for CBI (129-132).
However no method has been shown to completely control for these CBI outside
of true randomization, which is often unfeasible (133).
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1.3.2 Multivariable Regression Model
Multivariable regression models are common in statistical analysis of
observational studies. Regression models are used to model the likelihood of a
binary outcome. The actual model used should fit the data collected and should
be able to mathematically answer the questions posed in the study.
Logistic regression can only control for CBI on the condition that all the
variables in the model are measured accurately. Logistic regression is limited in
its ability to fully adjust a model for CBI because the number of variables that
would need to be included in the model is typically more than a study’s sample
size would allow. Typically in a model with a binary outcome it is assumed that a
minimum of ten patients will be needed per each predictor (or confounder)
variable in the model, with many studies suggesting 15-20 cases per variable
(134, 135). Missing data in any variable can affect the final sample size, so there
should be a larger number of patients recruited than are mathematically needed.
The multivariable regression model may also ignore complex relationships and
may not account for interactions or for nonlinear relationships between the
confounding variable and the outcome variable (e.g. if the health status of a
patient affects the type of treatment being given). Regression modeling also
cannot account for confounders that are unknown or unmeasured (136).
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1.3.3 Propensity Scoring
A propensity score is the probability of treatment assignment conditional
on observed baseline characteristics (137). Propensity scores are used to
balance confounding variables between study groups, mainly for predictor
variables (e.g. treatment type) that are provided to a patient in a non random
fashion (133, 137-139). Conditional on the propensity score, the distribution of
measured baseline covariates is similar between those with the treatment of
interest and those without the treatment (139).
A propensity score begins with a multivariable regression model that
estimates the joint effects on the primary predictor variable (e.g. the treatment)
with variables thought to be associated with the probability of receiving the
primary predictor variable (the treatment). A propensity score is usually defined
as the estimated probability of receiving the primary predictor variable. There is
debate regarding which variables to include in the creation of the propensity
score (139-141). However, it is agreed that a misspecified propensity score will
not completely balance confounding effects (142, 143).
Using a simplified formula for logistic regression is the first step in
developing a propensity score as follows:
Primary Predictor (Treatment) = ⍺ + Variable1 + Variable2 + … Variablen
The variables included in the regression model will change the likelihood
of an individual obtaining the primary predictor variable (e.g. treatment type). For
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example, if the predictor is a medication, such as a macrolide, the variables
included would be those that are associated with the probability of a patient being
prescribed that particular medication (e.g. variables that affect the propensity for
receiving the medication).
Each variable included in the propensity score should be theoretically
associated with the primary predictor variable and the outcome variable. It has
been recommended that models retain non-statistically significant predictors.
Also, removing pretreatment variables that are weakly associated with the
outcome will have biasing effects (144, 145). If the propensity score is created
from only covariates that are statistically significantly different between the
primary predictor and comparison groups, the score then fails to take into
account the relationship between the non-predictor variables and the outcome.
Relying heavily on sample size and not practical relevance causes covariates to
be considered in isolation rather than collectively (146, 147). Also, if iterative
model-building algorithms such as stepwise regression are used to select the
variables included in the propensity score, important confounders that may are
strongly related to the outcome but only weakly seen in the stepwise regression,
may not be included (147). Simulation studies have suggested that when
analyzing moderate-sized data sets, researchers should not exclude any variable
from the propensity score model unless it is well established that the variable has
no relationship to the outcome (142). Other studies have suggested that only
variables that are potential confounders and true confounders should be added
into the propensity score (148). It has also been suggested that variables
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included in the propensity score should affect the outcome but not the primary
predictor variable, and that including variables that affect the primary predictor
and not the outcome can increase the variance of the estimated treatment effect
without a reduction in bias (142, 147).
Given the lack of consensus on which variables to include in the model,
and knowing that it is difficult to correctly classify variables into the true
confounders (i.e. those that only affect the outcome, those that only affect
primary predictor, and those that affect neither treatment nor the outcome) it is
advisable to include all measured baseline characteristics in the creation of a
propensity score (147).
Once variable selection is made, the propensity score is then calculated
as the logit probability (which tends to be normally distributed) or the predicted
probability. The score is in the form of a continuous value, from 0 to 1, for each
individual in the study (139, 149).
Once the propensity score has been calculated for each of the patients in
the study, there are a variety of methods used to balance confounding.
Regression adjustment, stratified regression, or matching models are all common
approaches (137, 139, 150). Regression adjustment with a propensity score
occurs when the propensity score is used as an indication variable (indicating the
propensity to receive a treatment) that is placed into a regression model including
the primary predictor variable (treatment) and outcome. Propensity score
stratification occurs when there is stratification of subjects’ based on the
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individual subjects calculated propensity score. Within each propensity score
stratum the effect of a treatment on an outcome can be estimated and a more
specific risk can be estimated based on an individual’s propensity to receive a
treatment. Matching on a propensity score creates sets of exposed and
unexposed subjects who share a similar score (a similar indication to receive a
medication). Once a matched sample has been formed, the treatment effect can
be estimated by directly comparing outcomes between treated and untreated
subjects in the matched sample.
The propensity score matching approach should fit the research question
and specific hypotheses of the study. There are many forms of matching such as
Mahalanobis metric matching, nearest neighbor matching, caliper matching, and
nearest neighbor matching within a caliper. Nearest neighbor matching within a
caliper is a combination of matching approaches, and it allows for multivariable
analysis using the matched sample when the sample is sufficiently large (149,
151). Nearest neighbor matching with a caliper first randomly sorts both the
treatment and control groups. Then the first treatment unit is selected to find its
closest control match based on the absolute value of the difference between the
propensity score and that of the control under consideration. The closest control
unit within a certain number, the caliper, is selected as a match (149). Not using a
caliper can lead to poor balance between the treated and the control (i.e. those
without the treatment of interest) (151).
It is usually always appropriate to adjust for more confounding variables in
the final model. However, there may be confounding variables that are not
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included in the propensity score due to temporality concerns (149). Using the
previous example of antidepressant use in pregnancy and its effects on
pregnancy, confounding variables (e.g. diagnosis of depression, maternal age)
would be placed into the propensity score. The calculated propensity score would
then be used as the matching variable. This balances two non-equivalent groups
on observed characteristics thus there will be less biased estimates of the effects
of antidepressant use in pregnancy (152).
Propensity scores do not fully control for CBI as they do not account for
unmeasured confounding. Propensity scores only account for the confounding
variables included in the creation of the score. Since unmeasured variables can
influence receipt of the particular predictor variable, propensity scores cannot
completely remove the bias (149, 153).

1.3.4 Instrumental Variable Analysis
Although typically used in economics, instrumental variable analysis can
be useful in the determination of CBI. Instrumental variable (IV) analyses makes
use of an IV or an instrument to control for unmeasured variation between
confounders. This is different from propensity score matching, which is used to
controlled for measured variation between confounders (129, 154).
An instrument is a seemingly random variable that is strongly associated
with the predictor variable under study but not associated with the outcome
(Figure 3) (155).
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Figure 3. Diagram of Instrumental Variable

Finding an ideal instrument for any particular study is complicated. There
are three key assumptions used in the evaluation of an instrument (155). One,
the instrumental variable should lead to meaningful differences in the treatment
being tested. Two, other than through the specific treatment being tested, there
should be no other pathway for the instrumental variable to influence the
outcome. Three, the instrumental variable should not cause the patient to receive
both the instrument and the outcome. Otherwise stated, the IV should be
independent of any possible confounders, should have association with the risk
factor, and have independence of the outcome conditional on the risk factor and
confounders (156).
IV’s can vary in strength. The IV is considered weak when the variable
chosen is not a good estimator of the primary predictor variable and does not
explain a large proportion of the variation in the primary predictor (157-160). The
strength of the IV is typically determined by the F-statistic (161). The closer the Fstatistic is to zero, the weaker the instrument. For the maximum bias in IV
estimators to be less than 10%, the F-statistic should be greater than 10 (157).
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Weak instruments can create biased estimates and confidence intervals that are
inaccurate (158). Geographic variables from census data are often used as some
sort of an instrument, though the appropriateness of this instrument is based on
the dataset being analyzed (162).
Use of instrumental variables is normally done via a specific 2-stage
model. This method is recommended as it is based on the fewest assumptions
and will generate the most consistent IV estimates, even when the treatment and
outcome are binary variables (163-165). However, it can be biased in the
direction of the confounded association between the primary predictor variable
and outcome (166).
The first stage models the probability of the primary predictor variable as a
function of all of the confounding variables and the instrumental variable. In
comparison, the second stage again includes the confounding variables along
with the predicted probability of the treatment from the first stage (132). The
output of the model explains the impact of the probability of treatment on the
outcome versus the presence or absence of the treatment (132, 155).
With the previous example of antidepressant use in pregnancy and its
effects on pregnancy, an instrumental variable could be health insurance status.
Having health insurance could influence a mother’s ability to obtain
antidepressants during pregnancy, but should have no influence on the
development of autism in a child. Health insurance status is then used to remove
variation in the treatment so that it is free of the unmeasured confounders. Then
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the confounder-free variation in the treatment can be used to estimate the
causal effect of antidepressant use in pregnancy on autism development (159,
162, 167).
The inherent limitation for instrumental variable analyses is their strong
dependence on the assumption that the instrument is independent of all the
variables that have an effect on both the predictor variable and the outcome
variable, and that the instrument is independent of the outcome variable (132).
Instrumental variable analysis is a large-sample procedure, meaning there is
some bias due to sample-size limitations, even if all the assumptions of an
appropriate instrument are met (132, 168).

1.5 Conclusions
Current guidelines for the treatment of hospitalized patients with CAP
include empiric antimicrobial therapy with a macrolide plus a beta-lactam. There
is little consensus among studies as to which antimicrobial regimen is best. The
confusing results seen may be due to a lack of assessment of CBI. Thus, the
objective of this study is to evaluate the impact of empiric macrolide therapy on
early clinical improvement and 30 day mortality of hospitalized patients with CAP.
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AIMS AND HYPOTHESES

2.1.1 Aim:
To evaluate three years of study data and determine whether macrolide
and beta-lactam combination therapy usage is appropriate for gold standard
treatment in hospitalized community acquired pneumonia though assessment of
ECS and 30 day mortality.

2.1.2 Hypothesis:
Patients with macrolide and beta-lactam combination therapy will reach
ECS and will have decreased 30 day mortality compared to those who have
been given a different antibiotic.

2.2.1 Aim:
To assess and compare various methods addressing CBI (multivariable
logistic regression, propensity score stratification and matching, instrumental
variable analysis) through the assessment of macrolide and beta-lactam
combination therapy and its effect on ECS and 30 day mortality in hospitalized
patients with community acquired pneumonia.
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2.2.2 Hypothesis:
The three methods assessing CBI will show the same effects of macrolide
and beta-lactam combination therapy on ECS and 30 day mortality.
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MATERIALS AND METHODS

3.1 Study

This is a secondary analysis of years one, two, and three of the
Hospitalized Adults with Pneumococcal Pneumonia: Incidence Study (HAPPI).
This study was conducted in Jefferson County, Kentucky from 2014 to 2017. It
was a prospective population based cohort of adults hospitalized with CAP within
the participating hospitals (n=8839) (7).

The study was approved by the Institutional Review Board (IRB) at the
University of Louisville Human Subjects Research Protection Program Office
(IRB number 11.0613) and by the research offices at each participating hospital.
The study was exempt from informed consent.

3.1 Inclusion Criteria

Patients with CAP in one of nine area hospitals in Jefferson County,
Kentucky were recruited into the study. The nine area hospitals included Baptist
East Hospital, Jewish Hospital, Norton Audubon Hospital, Norton Brownsboro
Hospital, Norton Downtown Hospital, Norton Suburban Hospital, St. Mary and
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Elizabeth Hospital, University Hospital, and Veteran’s Affairs Hospital. A patient
was defined as having CAP when the following 3 criteria were met: (1) presence
of a new pulmonary infiltrate on chest radiograph and/or chest computed
tomography scan at the time of hospitalization, defined by a board-certified
radiologist’s reading; (2) at least 1 of the following: (a) new cough or increased
cough or sputum production, (b) fever >37.8°C (100.0°F) or hypothermia <35.6°C
(96.0°F), (c) changes in leukocyte count (leukocytosis: >11000 cells/µL; left shift:
>10% band forms/mL; or leukopenia: <4000 cells/µL); and (3) no alternative
diagnosis at the time of hospital discharge that justified the presence of criteria 1
and 2 (7). These criteria were adapted from prior investigations (169, 170).
Patients with CAP were included in this analysis upon the determination of
antibiotic use within the first 24 hours of admission.

3.2 Exclusion Criteria

Patients were excluded from HAPPI if they did not have a permanent or
valid Jefferson County, KY address based on US Census Bureau data, did not
have a valid Social Security number (SSN), or were in the correctional system
(7). Patients missing data needed to determine ECS were excluded in this
analysis. Patients were also excluded from this analysis if they were given both a
macrolide and a fluoroquinolone, or a non-macrolide and non-beta-lactam
combination therapy with a non-fluoroquinolone substitute in the first 24 hours.
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After exclusion and missing data attrition, the study sample size for this analysis
was 3142 participants (Figure 4).

3.3 Exposure: Macrolide Usage

Two groups were created from the patients that were included in this
analysis. Group 1 consisted of patients who received a macrolide plus a betalactam in the first 24 hours of admission but did not receive a fluoroquinolone,
n=1904 (Figure 4). Macrolide antimicrobials are as follows: Azithromycin,
Clarithromycin, and Erythromycin. Beta-lactam antimicrobials are as follows:
Amoxicillin, Amoxicillin/Clavulanate, Ampicillin, Ampicillin/Sulbactam, Cefaclor,
Cefazolin, Cefepime, Cefixime, Cefoperazone, Cefoperazone-Sulbactam ,
Cefotaxime, Cefotetan, Cefpodoxime, Ceftazidime, Ceftriaxone, Cefuroxime,
Cephalexin, Cloxacillin, Dicloxacillin, Imipenem/Cilastin, Meropenem, Nafcillin,
Penicillin, Penicillin G, Piperacillin, Piperacillin/Tazobactam, and Ticarcillin/
Clavulanic acid.

Group 2 consisted of patients who received a non-macrolide regimen,
n=1238 (Figure 4). Quinolone antimicrobials are as follows: Levofloxacin,
Gatifloxacin, Moxifloxacin and Ciprofloxacin.
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8839

Living in Jeﬀerson County

8772

Antibiotic information

8769

Admission data

8479

Antibiotic in the first 24 hours

3142

Macrolide + Beta-lactam or
Fluoroquinolone

67

3

290

5336

Macrolide +
Beta-lactam

1904

1238

Fluoroquinolone

Figure 4. Flow chart showing sample selection for analysis
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3.4.1 Outcome: Early Clinical Stability

Clinical stability is defined according to the ATS guidelines published in
2001. The ATS criteria are as follows: improved symptoms of pneumonia (cough
and shortness of breath), lack of fever for at least eight hours, improving
leukocytosis (decreased at least 10% from the previous day), and ability to take
oral medications (97). All the criteria should be present during the same day in
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comparison to the previous day to define clinical stability (97). For this study,
ECS was to have occurred when the criteria were met on or before the third day
of hospitalization. The dependent variable of this study was ECS by day 3 of
hospitalization.

3.4.3 Outcome: 30 Day Mortality

The outcome of 30 day mortality was defined as all-cause mortality up to
30 days after hospitalization. Mortality was obtained through medical record
abstraction and using data from the Kentucky Department for Public Health
Office of Vital Statistics (7).

3.5.1 Other Variables

The original HAPPI study collected more than 600 variables. As analyzing
all of these variables is outside the scope of this analysis, a determination of
what variables to include was necessary. The variables included in the statistical
analysis were important to the risk of CAP, associated with macrolide usage,
associated with ECS, factors in clinical presentation, or were demographic
variables. Demographic variables included were age, sex and race. Medical
history variables included history of intravenous (IV) drug use, alcoholism,
asplenia, chronic renal failure, congestive heart failure (CHF), cirrhosis, chronic
obstructive pulmonary disease (COPD), cerebrovascular disease (CVD), human
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immunodeficiency virus (HIV), diabetes, history of IV steroid use before day 0 of
admission, liver disease, history of neoplastic disease within the last year or
current neoplastic disease, renal disease, residence in a nursing home, current
smoker status, and suspicion of risk for aspiration. Variables that were collected
in the initial physical exam in the hospital included body mass index (BMI),
diastolic blood pressure (DBP), systolic blood pressure (SBP), heart rate (HR),
respiratory rate (RR), temperature, and weight. Variables that were found on the
initial physical exam in the hospital included body mass index (BMI), diastolic
blood pressure (DBP), systolic blood pressure (SBP), heart rate (HR). respiratory
rate (RR), temperature, and weight. Initial laboratory finding variables included
blood urea nitrogen (BUM), serum glucose, hematocrit percent, and serum
sodium. Variables that influenced the level of severity of CAP include altered
status on admission, being admitted directly to the intensive care unit from the
emergency department, requiring vasopressors on day 0 of admission, and
requiring ventilatory support on day 0 of admission. Another variable considered
was the classification of “severe”. This variable was created from a score based
on the severity criteria recommended by the ATS/IDSA and compiled from the
following variables (3, 171):

- Respiratory rate >30 breaths per minute
- Partial pressure of oxygen dissolved in the blood divided by fractional
inspired oxygen (PaO2/FiO2) </=250

- Multi-lobar pneumonia as seen on a CT
- BUN >/= 20 mg/dL
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- Leukopenia (white blood count >20,000/microL)
- Thrombocytopenia (platelets <100,000/microL)
- Hypothermia (temperature < 36 degrees Celsius)
- Hypotension (SBP<90mmHg and DBP<60mmHg
- Ventilator type (nasal intermittent mandatory ventilation (NMIV))
- Altered mental status on admission
- Septic shock
- Vasopressor medication
Census tract block information from patients was used in the instrumental
variable analysis.

3.5.2 Instrumental Variable

Area Deprivation Index (ADI) was assessed as an appropriate
instrumental variable. ADI is defined as a geographic area-based measure of the
socioeconomic deprivation experienced by a neighborhood and is determined
from census information. Higher ADI values represent higher levels of deprivation
(172). ADI is based on the following indicators: median family income, income
disparity, occupational composition, unemployment rate, family poverty rate,
percentage of the population below 150% of the poverty limit, single-parent
household rate, home ownership rate, median home value, median gross rent,
median monthly mortgage, household crowding, and percentages of households
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without access to a telephone, plumbing, or motor vehicles. Factor analysis and
principal-components analysis were used in index construction (173).

3.6.1 Sample Size and Statistical Power

The initial study sample had 8839 participants, but after attrition due to
exclusion criteria and missing data, the total sample size was 3,142, with 1,904 in
group 1 and 1,238 in group 2.

Of those who gained ECS (n=2,018), 57.7% were given macrolide and
beta-lactam combination therapy (n=1,205). The risk of ECS among group 1 was
63.29%. The risk of ECS among group 2 was 65.67%. Given the expected
frequencies of exposure, an OR of 1.28 at 80% power and 1-alpha of 95% is
detectable, the inverse of which is an OR of 0.78. Although, with the given
sample size, a post hoc power analysis showed the statistical analysis of ECS
was under-powered at 27.81% (174).

Of those who died within 30 days of discharge from the hospital (n=224),
60.3% were given macrolide and beta-lactam combination therapy (n=125). The
risk of 30 day mortality among group 1 was 7.09%. The risk of ECS among group
2 was 7.19%. Given the frequencies of exposure, an OR of 1.5 at 80% power
and 1-alpha of 95% is detectable, the inverse of which is an OR of 0.67.
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However, with the given sample size, a post hoc power analysis showed the
statistical analysis for 30 day mortality was under-powered at 2.18% (174).

Further statistical analysis were performed using STATA 14 and R.

Fisher's Exact Test was used on categorical variables and the MannWhitney U/ Wilcoxon Sum-rank test was used on continuous variables to
understand the characteristics of the population and to assess variables for
inclusion in further analysis. Inclusion was determined to occur at a conservative
p-value of <0.20. Variables initially included were organized by type demographic variables, medical history, physical findings on initial exam,
laboratory findings on initial exam, and severity of CAP (Table 4).

3.6.2 Statistical Analysis of Confounding and Confounding By Indication
The effect of macrolide usage on ECS was assessed using multiple
statistical methods: multivariable logistic regression, stratification using the
propensity score, propensity score matching, and instrumental variable analysis.
After the primary analysis determining which variables are statistically
significantly different between the two groups, using P<= 0.2, the significant
variables were placed into the multivariable logistic regression model. The final
model was determined through a data-based method for assessment (125). A full
model with the statistically significant variables was made. Then starting with the
full model each covariate was removed, one at time. When the beta coefficient of
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macrolide and beta-lactam therapy was more than 10% different than original full
model beta coefficient of macrolide and beta-lactam therapy, the variable will be
considered for the full model. The variable that was least significant, the one with
the largest P value that did not affect the beta coefficient of macrolide and betalactam therapy more than 10%, was removed and the remaining variables went
through the same process till only the confounding variables remained. A
bidirectional stepwise method was also used, which is a mix of the forward and
backward methods. (Forward stepwise regression is when variables are
introduced one by one, beginning with the strongest, and then stopping when
addition of the next factor does not significantly improve AIC. Backward stepwise
regression is where all the variables are initially introduced and then are
withdrawn one by one until the overall AIC does not deteriorate (175, 176).) The
results of the bidirectional stepwise method were compared to the data-based
method for assessment.
Propensity scores were calculated by a logit regression. The propensity
score was created using all of the demographic characteristic variables, except
for those that were included in the severity score (Table 4) (142, 143). These
variables were: age, sex, race, mental status, history of neoplastic disease, CHF,
CVA, COPD, renal disease, chronic renal failure, liver disease, cirrhosis,
asplenia, alcoholism, suspicion of aspiration, IV steroid use, IV drug use, HIV,
nursing home status, smoking status, direct ICU admission, exam HR, exam
BMI, hematocrit laboratory values, glucose laboratory values, and sodium
laboratory values. The propensity score was established by creating the
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predicted probability of receiving the macrolide and beta-lactam combination
treatment given the set of variables described above.

Propensity scores were used to stratify the population. Patients were
ranked according to propensity score and stratified into propensity score
quintiles, an approach that is known to remove the majority of bias in measured
covariates (177). Also, patients receiving macrolide and beta-lactam combination
therapy (group 1) were matched with patients that did not receive the
combination therapy (group 2) according to their propensity scores. The 1:1
matched analysis was performed using caliper width based on the propensity
score (178). The caliper width was determined by taking the standard deviation
of the propensity score and multiplying it by 0.25.
Instrumental Variable Analysis were performed using the multivariable
logistical regression and the two stage probit model with a significant instrument,
that was determined by the F-statistic being greater than 10. The probit
coefficient created by the model was multiplied by 1.6 and then exponentiated to
approximate an Odds Ratio (OR) such that the outcomes of the various methods
for addressing confounding by indication could be compared to one another
(165).
The results from the different models were compared by placing them into
a forest-like plot. A confidence interval that excluded the OR’s from other
methods was considered significantly different.
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RESULTS

4.1 Population

In the original study population, there were 8,839 participants with CAP
included who all lived in Jefferson County. 8,772 had antibiotic information listed,
with 8,769 of those having admission data. There were only 8,479 participants
who received an antibiotic within the first 24 hours. Of these, only 3,141 received
either macrolide and beta-lactam combination therapy (N=1,905) or
flouroquinolone mono-therapy (N=1,238) (Figure 4).

Table 4 shows descriptive statistics for the study population. Among the
demographic variables neither sex nor race were significantly different between
the groups. Age was significantly different between the groups, p=0.001, with 65
as the mean age in group 1 and 67 as the mean age in group 2 (Table 4).
Of the medical history variables, history of intravenous drug use, CHF,
cirrhosis, COPD, history of IV steroid use before day 0 of admission, residence in
a nursing home, and current smoker status were significantly different between
the two different groups, given p<0.2 (Table 4). Interestingly, nursing home status
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was most significant (p=<0.001) with 74 in a nursing home in group 1 (4%) and
102 in a nursing home in group 2 (8%).
Of the variables that were found on the initial physical exam in the hospital
DBP, SBP, HR and RR were all significantly different between groups (given
p<0.2), with p-values of <0.001, 0.001, 0.002, and <0.001, respectively (Table 4).
From the initial laboratory finding variables, hematocrit percent was found to
be significantly different (given p<0.2) between the two groups, (p=0.001) (Table
4). The mean hematocrit percentage was 36.1% in group 1 and 36.9% in group
2. Serum glucose was also noted to be different between the two groups,
p=0.012, with 170 mg/dL the mean in group 1 and 160 mg/dL the mean in group
2.
Of the variables that influenced the severity of CAP, ventilator support on
day zero was significant (given p<0.2), p=0.032, with 179 (9%) in group 1 and 84
(7%) in group 2 (Table 4).
Severe was a significant variable (given p<0.2), p=0.005, with 602 people in
group 1 and 333 in group 2. There were many variables that were included in the
severe variable that were also examined. Some of these variables were
independently significant while others were not. To prevent variables from being
used twice in the analysis, the decision was made to include the severe variable
as it carries a wider range of disease information with it.
Other correlated variables were COPD and IV steroid use before day 0 of
admission (0.3414, p-value=< 0.001). This correlation is most likely a result of IV
steroids given for exacerbations COPD (179).
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Table 4. Characteristics of Study Population by Antibiotic Therapy Type
Macrolide +
Beta-Lactam
Combination
Therapy

Fluoroquinolone
Mono-therapy
Therapy

African American/Black, n (%)

376 (20)

239 (19)

0.783

Age, Mean (SD)

65 (17)

67 (16)

0.001+

Male Gender, n (%)

840 (44)

540 (44)

0.797

Active intravenous drug use?, n (%)

31 (2)

10 (1)

0.053+

Alcoholic, n (%)

96 (5)

58 (5)

0.673

Asplenia, n (%)

4 (0)

3 (0)

>0.999

Chronic renal failure, n (%)

120 (6)

80 (6)

0.881

Congestive heart failure, n (%)

481 (25)

343 (28)

0.135+

Cirrhosis, n (%)

16 (1)

4 (0)

0.106+

COPD, n (%)

868 (46)

617 (50)

0.019+

Cerebrovascular disease, n (%)

206 (11)

138 (11)

0.770

Diabetes, n (%)

589 (31)

368 (30)

0.500

HIV, n (%)

25 (1)

16 (1)

>0.999

IV steroids on day 0, n (%)

598 (31)

343 (28)

0.028+

Liver disease, n (%)

127 (7)

71 (6)

0.329

Neoplastic disease (active or within the last
year), n (%)

204 (11)

141 (11)

0.56

Renal disease, n (%)

469 (25)

309 (25)

0.833

Nursing home resident, n (%)

74 (4)

102 (8)

<0.001+

Current smoker, n (%)

689 (36)

396 (32)

0.017+

Suspicion of aspiration, n (%)

132 (7)

87 (7)

0.943

Characteristics

P-value

Demographic Variables

Medical History

+, variables will be included in further analysis as p-value<0.2
**, variables will not be included in analysis due to the inclusion in severity variable
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Table 4 continued. Characteristics of Study Population by Antibiotic Therapy Type
Macrolide +
Beta-Lactam
Combination
Therapy

Fluoroquinolone
Mono-therapy
Therapy

BMI (kilograms/meter^2), Mean (SD)

29.1 (9)

28.8 (8.6)

0.476

Diastolic blood pressure (mmHg), Mean (SD)

60.8 (17.9)

63.5 (17)

<0.001**

Systolic blood pressure (mmHg), Mean (SD)

121.2 (27.4)

124.1 (25.9)

0.001**

Heart rate (Beats/Minute), Mean (SD)

105.2 (22.1)

102.8 (21.5)

0.002+

Respiratory rate (Breaths/Minute), Mean (SD)

23.7 (6.5)

23 (6.5)

<0.001**

Temperature (Degrees Celsius), Mean (SD)

37.4 (9)

37.4 (0.8)

0.798**

Weight (kilograms), Mean (SD)

82.6 (27)

82 (26)

0.555

Blood Urea Nitrogen (BUN) (mg/dL), Mean
(SD)

22.1 (16.4)

21.2 (13.8)

0.696**

Serum glucose (mg/dl), Mean (SD)

170.4 (88.6)

160.8 (78)

0.012+

Hematocrit(%), Mean (SD)

36.1 (6.1)

36.9 (6)

0.001+

Serum sodium (mEq/L), Mean (SD)

136.7 (5)

136.5 (4.6)

0.297

CAP diagnosis is considered severe, n (%)

602 (32)

333 (27)

0.005+

Altered mental status on admission, n (%)

219 (11)

139 (11)

0.863**

Was the patient admitted directly to an
intensive care unit from the emergency
department?, n (%)

188 (10)

108 (9)

0.289

Did the patient need vasopressors on day 0?,
n (%)

24 (1)

14 (1)

0.868**

84 (7)

0.032**

Characteristics

P-value

Physical Findings on Initial Exam

Initial Laboratory Findings

Severity of CAP

Did the patient need ventilatory support on day 170 (9)
0?, n (%)

+, variables will be included in further analysis as p-value<0.2
**, variables will not be included in analysis due to the inclusion in severity variable
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Variables included in further analysis were as follows: age, cirrhosis,
COPD, CHF, history of IV drug use, being in a nursing home, currently smoking,
HR, hematocrit, glucose, and severity.

4.2.1 Assessment of Macrolide Combination Therapy and the Effects on Early
Clinical Stability: Logistic Regression

Patients on macrolide and beta-lactam combination therapy were less
likely to reach ECS than those taking fluoroquinolones, although this is a non
significant result (OR 0.901; 95% Confidence Interval (CI) 0.776, 1.047; p-value:
0.173) (Table 5).

In the full model including all the variables that were found to be
significantly different (given p<0.2) between group 1 and 2 (age, cirrhosis, COPD,
CHF, history of IV drug use, being in a nursing home, currently smoking, HR,
hematocrit, glucose, and severity) macrolide combination therapy was found to
decrease the likelihood of reaching ECS, although this also was non-significant
(OR 0.911; 95% CI 0.780, 1.063; p-value = 0.235). Significant variables in this
model were COPD (OR 0.747; 95% CI 0.638, 0.875; p-value =<0.001), HR (OR:
0.992; 95% CI 0.988, 0.995; p-value =<0.001), CHF (OR 0.802; 95% CI 0.675,
0.953 ; p-value =0.012), and severity (OR 0.611; 95% CI 0.519, 0.721; p-value
=<0.001) (Table 5).
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The bidirectional stepwise analysis algorithm yielded the same model
results that the data-based method of variable selection did (both algorithms
used macrolide combination therapy as the primary predictor variable). The
model was as follows: logit P(ECS) = ⍺ + β1(macrolide and beta-lactam
combination therapy) + β2(COPD) + β3(CHF) + β4(residence in a nursing home) +
β5(HR) + β6(severity) + ε. The reduced model was not statistically different from
the full model and was thus considered acceptable (Chi-Square P-value =
0.8641289). In the final model, macrolide and beta-lactam use was associated
with decreased odds of gaining ECS, although this was once again not
statistically significant (OR 0.910; 95% CI 0.780, 1.061; p-value =0.227). The
variables in this model that were significantly associated with increased time to
clinical stability were COPD (OR 0.735; 95% CI 0.633, 0.854; p-value =<0.001),
HR (OR: 0.992; 95% CI 0.988, 0.995; p-value =<0.001), CHF (OR 0.810; 95% CI
0.675, 0.953 ; p-value =0.015), and severity (OR 0.617; 95% CI 0.526, 0.725; pvalue =<0.001) (Table 5). The full process for variable selection using a databased method is presented in Appendix II (ECS: Multivariable Logistic
Regression, Data-based Method for Assessment).
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Table 5. Multivariable Logistic Regression Models: ECS
Variable

OR

95% CI

P-Value

0.901

0.776, 1.047

0.173

0.911

0.780, 1.063

0.235

Age

>0.999

0.995, 1.005

0.984

Glucose

>0.999

0.999, 1.001

0.756

Smoking

0.954

0.802, 1.136

0.599

IV drug use

0.818

0.427, 1.565

0.543

Cirrhosis

0.738

0.302, 1.805

0.506

Hematocrit

0.993

0.981, 1.006

0.301

Residence in nursing home

0.740

0.537, 1.018

0.065

CHF

0.802

0.675, 0.953

0.012 +

COPD

0.747

0.638, 0.875

<0.001 +

HR

0.992

0.988, 0.995

<0.001 +

Severe

0.611

0.519, 0.721

<0.001 +

Macrolide + Beta Lactam Therapy

0.910

0.780, 1.061

0.227

Residence in nursing home

0.752

0.548, 1.032

0.078

CHF

0.810

0.683, 0.959

0.015 +

COPD

0.735

0.633, 0.854

<0.001 +

HR

0.992

0.988, 0.995

<0.001 +

Severe

0.617

0.526, 0.725

<0.001 +

Univariate Model
Macrolide + Beta Lactam Therapy

Full Model
Macrolide + Beta Lactam Therapy

Final Model

+ statistically significant
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4.2.2 Assessment of Macrolide Combination Therapy and the Effects on 30 Day
Mortality: Logistic Regression

Assessing the unadjusted effects of macrolide and beta-lactam
combination therapy and its effect on 30 day mortality showed that those with
macrolide and beta-lactam combination therapy were less likely to have died
within 30 days of admission, although this is a non-significant result (OR 0.985;
95% Confidence Interval (CI) 0.746, 1.301; p-value: 0.916) (Table 6).

The full model including all the variables that were found to be significantly
different (given p<0.2) between group 1 and 2 (age, cirrhosis, COPD, CHF,
history of IV drug use, being in a nursing home, currently smoking, HR,
hematocrit, glucose, and severity) macrolide combination therapy was found to
decrease 30 day mortality, although this again was non significant (OR 0.911;
95% CI 0.780, 1.063; p-value = 0.235). Significant variables in this model were
Age (OR 1.04; 95% CI 1.029, 1.052; p-value =<0.001), HR (OR: 1.014; 95% CI
1.007, 1.020; p-value =<0.001), IV drug use (OR 3.486; 95% CI 1.121, 10.838 ;
p-value =0.031), hematocrit (OR 0.950; 95% CI 0.928, 0.973 ; p-value =<0.001),
and severity (OR 2.237; 95% CI 1.675, 2.987; p-value =<0.001) (Table 6).

The bidirectional stepwise analysis algorithm produced a different model
result than the data-based method variable selection (both algorithms used
macrolide combination therapy as the primary predictor variable). Both models
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included residence in a nursing home, history of IV drug use, hematocrit lab
values, HR, severity, and age. The bidirectional stepwise method included CHF
while the data-based method included glucose values. Neither the bidirectional
stepwise method nor the data-based method were statistically different from the
full model, Chi-Square P-value of 0.3306626 and 0.4590019, respectively. The
data-based method model was less different from the full model compared to the
bidirectional stepwise method. The model was as follows: logit P(30 Day
Mortality) = ⍺ + β1(macrolide and beta-lactam combination therapy) +
β2(residence in a nursing home) + β3(glucose) + β4(IV drug use) + β5(hematocrit)
+ β6(HR) + β7(severe) + β8(age) + ε.

In the final model, those with macrolide and beta-lactam use were less
likely to have died within 30 days of admission, although this was not statistically
significant (OR 0.926; 95% CI 0.692, 1.241; p-value =0.608). The variable in this
model that was significantly associated with reduced mortality was hematocrit
(OR: 0.950; 95% CI 0.928, 0.973; p-value =<0.001). The variables in this model
that were significantly associated with increased 30 day mortality were IV drug
use (OR 3.548; 95% CI 1.160, 10.854; p-value =0.026), HR (OR 1.013; 95% CI
1.007, 1.019 ; p-value =<0.001), severity (OR 2.290; 95% CI 1.717, 3.052; pvalue =<0.001), and age (OR 1.042; 95% CI 1.031, 1.053; p-value =<0.001)
(Table 6). The full process for variable selection using a data-based method is
presented in Appendix II (30 Day Mortality: Multivariable Logistic Regression,
Data-based Method for Assessment).
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Table 6. Multivariable Logistic Regression Models: 30 Day Mortality
Variable

OR

95% CI

P-Value

0.985

0.746, 1.301

0.916

Macrolide + Beta Lactam Therapy

0.929

0.780, 1.063

0.235

Smoking

0.955

0.663, 1.376

0.804

COPD

1.068

0.795, 1.435

0.663

CHF

1.221

0.902, 1.653

0.196

Residence in nursing home

1.387

0.856, 2.248

0.184

Cirrhosis

2.486

0.690, 8.963

0.164

Glucose

1.001

1.000, 1.003

0.094

IV drug use

3.486

1.121, 10.838

0.031 +

Hematocrit

0.950

0.928, 0.973

<0.001 +

HR

1.014

1.007, 1.020

<0.001 +

Severe

2.237

1.675, 2.987

<0.001 +

Age

1.040

1.029, 1.052

<0.001 +

Macrolide + Beta Lactam Therapy

0.926

0.692, 1.241

0.608

Glucose

1.001

1.000, 1.003

0.066

Residence in nursing home

1.390

0.859, 2.249

0.180

IV drug use

3.548

1.160, 10.854

0.026 +

Hematocrit

0.950

0.928, 0.973

<0.001 +

HR

1.013

1.007, 1.019

<0.001 +

Severe

2.290

1.717, 3.052

<0.001 +

Age

1.042

1.031, 1.053

<0.001 +

Univariate Model
Macrolide + Beta Lactam Therapy
Full Model

Final Model

+ statistically significant
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4.3.1 Propensity Score Creation

The calculated propensity score ranged from 0.2718 to 0.9007 as depicted
in the histogram in Figure 5. The mean propensity score was 0.6060 with a
standard deviation of 0.0869. Group 1 had a mean of 0.6184 while group 2 had a
mean of 0.5868 and were statistically different from one another (p= <0.001)
(Figure 6). The propensity scores between the two groups, while visually similar,
are not statistically similar, meaning that on average, those who were given
fluoroquinolone mono-therapy had a slightly lower probability of being given
macrolide and beta-lactam combination therapy.

Histogram of Propensity Score
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Figure 5. Histogram of Propensity Scores
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Figure 6. Histogram of Propensity Scores by Treatment Type

!

Using the calculated propensity score, patients in group 1 were matched
with patients in group 2. Nearest neighbor matching with a caliper was used to
create the matches. The caliper, 0.02173275, was based on the standard
deviation of the propensity score, multiplied by 0.25. Of the original 3142
patients, 1177 matched pairs were created, leaving 61 people in group 2
unmatched and 727 people in group 1 unmatched (Figure 7, Figure 8).
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Figure 7: Distribution of Propensity Scores

!

!

Figure 8: Distribution of Propensity Scores, Matched vs Unmatched
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4.3.2 Assessment of Macrolide Combination Therapy and the Effects on Early
Clinical Stability: Propensity Score Analysis

Using conditional logistic regression, macrolide and beta lactam usage
was found to decrease the likelihood of gaining clinical stability, although this was
non-significant (OR 0.885, 95% CI 0.748, 1.048, p-value = 0.156) (Table 7).

When the propensity scores were stratified based on quartile values, the
effect of macrolide and beta-lactam combination therapy on ECS was assessed
using logistic regression. While none of the values were significant, the effect of
macrolide and beta-lactam combination therapy on establishing ECS did change
depending on the propensity score value (Table 7).

Table 7. Effects of Macrolide and Beta-Lactam Combination Therapy on ECS, by Propensity
Score
Model

OR

95% CI

P-value

0.885

0.748, 1.048

0.156

Conditional Logistic Regression
Matched 1:1

Stratification by PS
Q1

0.0001 - 0.5571

0.888

0.660, 1.196

0.435

Q2

0.5572 - 0.6109

0.927

0.684, 1.257

0.625

Q3

0.6110 - 0.6631

1.023

0.755, 1.386

0.884

Q4

0.6632 - 1.0000

0.929

0.679, 1.271

0.646
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4.3.2 Assessment of Macrolide Combination Therapy and the Effects on 30 Day
Mortality: Propensity Score Analysis

Using conditional logistic regression, macrolide and beta lactam usage
was found to decrease 30 day mortality, although this was non-significant (OR
0.848, 95% CI 0.612, 1.174, p-value = 0.321) (Table 8).

When the propensity scores were stratified based on quartile values, the
effect of macrolide and beta-lactam combination therapy on 30 day mortality was
assessed using logistic regression. While none of the values were significant, the
effect of macrolide and beta-lactam combination therapy on 30 day mortality did
change depending on the propensity score value, particularly in the third quartile
(Table 8).

Table 8. Effects of Macrolide and Beta-Lactam Combination Therapy on 30 Day Mortality by
Propensity Score
Model

OR

95% CI

P-value

0.885

0.748, 1.048

0.156

Conditional Logistic Regression
Matched 1:1

Stratification by PS
Q1

0.0001 - 0.5571

0.955

0.566, 1.612

0.863

Q2

0.5572 - 0.6109

0.954

0.501, 1.815

0.885

Q3

0.6110 - 0.6631

1.240

0.697, 2.207

0.465

Q4

0.6632 - 1.0000

0.797

0.465, 1.366

0.409
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4.4.1 Assessment of Macrolide Combination Therapy and the Effects on Early
Clinical Stability: Instrumental Variable Analysis

Instrumental variable analysis was done via a two stage model where the
first-stage was a regression of macrolide and beta-lactam combination therapy
and other variables on the instrumental variable, ADI. The second-stage was a
regression of ECS on the fitted values of the risk factors from the first stage. ADI
was considered a strong instrument as the F-statistic was greater than 10 (Fstatistic 12.62; p-value <0.001). The model used in this analysis included the
variables selected in logistic regression modeling, COPD + CHF + residence in a
nursing home + HR + severity.

While the confidence interval was very wide and non-significant, it is
interesting to note that macrolide and beta-lactam combination therapy was
associated with reaching ECS (OR 1.551; 95% CI 0.778, 3.091; p-value = 0.213).
The significant variables in this model were CHF (OR 0.935; 95% CI 0.876,
0.999; p-value = 0.046), COPD (OR 0.915; 95% CI 0.858, 0.976; p-value =
0.007), HR (OR 0.996; 95% CI 0.995, 0.998; p-value = <0.001), and Severity
(OR 0.810; 95% CI 0.750, 0.874; p-value = <0.001) (Table 9).
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Table 9. Instrumental Variable Analysis with ADI as the Instrument: ECS
Variable

OR

95% CI

P-Value

Macrolide + Beta Lactam Therapy

1.551

0.778, 3.091

0.213

Residence in nursing home

0.989

0.824, 1.187

0.907

CHF

0.935

0.876, 0.999

0.046 +

COPD

0.915

0.858, 0.976

0.007 +

HR

0.996

0.995, 0.998

<0.001 +

severe

0.810

0.750, 0.874

<0.001 +

+ statistically significant

4.4.2 Assessment of Macrolide Combination Therapy and the Effects on 30 Day
Mortality: Instrumental Variable Analysis

Instrumental variable analysis was done via the two stage model. ADI was
again considered a strong instrument as the F-statistic was greater than 10 (Fstatistic 11.03; p-value <0.001). The model used in this analysis included the
variables selected in logistic regression modeling, glucose + residence in a
nursing home + history of IV drug use + hematocrit lab values + HR + severity +
age.

While the confidence interval was non-significant, macrolide and betalactam combination therapy was associated with a slight decrease in the
likelihood of dying within 30 days (OR 0.958; 95% CI 0.603, 1.522; p-value
=0.857). The significant variables in this model were hematocrit (OR 0.995; 95%
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CI 0.991, 0.998; p-value = 0.002), HR (OR 1.002; 95% CI 1.001, 1.002; p-value =
<0.001), severity (OR 1.108; 95% CI 1.064, 1.154; p-value = <0.001), and age
(OR 1.003; 95% CI 1.002, 1.005; p-value = <0.001) (Table 10).

Table 10. Instrumental Variable Analysis with ADI as the Instrument: 30 Day Mortality
OR

95% CI

P-Value

Macrolide + Beta Lactam Therapy

0.958

0.603, 1.523

0.857

Glucose

1.000

1.000, 1.000

0.217

Residence in nursing home

1.052

0.944, 1.173

0.359

IV drug use

1.105

0.966, 1.264

0.145

Hematocrit

0.995

0.991, 0.998

0.002 +

HR

1.002

1.001, 1.002

<0.001 +

Severe

1.108

1.064, 1.154

<0.001 +

Age

1.003

1.002, 1.005

<0.001 +

Variable

+ statistically significant

4.2.5 Assessment of Methods Addressing Confounding by Indication: Logistic
Regression, Propensity Score Matching, Instrumental Variable Analysis

Figures 8 and 9 compare the results from the three methods for controlling
confounding and confounding by indication in a forest plot. Examining the
methods used to assess the effects of macrolide and beta-lactam combination
therapy on ECS, the OR’s of all three methods have non-significant intervals and
the OR’s from logistic regression and propensity score matching are almost
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identical, 0.918 and 0.916 respectively, (Table 9). The methods used to assess
the effects of macrolide and beta-lactam combination therapy on 30 day mortality
all had similar OR’s with non significant intervals (Figure 9, Table 9). The
confidence intervals from the instrumental variable analyses preformed are larger
than those from logistic regression and propensity score matching.

Table 11. Comparing Logistic Regression, Propensity Score Matching, and Instrumental
Variable Analysis
Method

OR

95% CI

Logistic Regression

0.908

0.780, 1.059

Propensity Score Match

0.916

0.775, 1.083

Instrumental Variable Analysis

1.551

0.777, 3.091

Logistic Regression

0.926

0.692, 1.241

Propensity Score Match

0.885

0.748, 1.048

Instrumental Variable Analysis

0.958

0.603, 1.523

ECS

30 Day Mortality
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Figure 8: Forest-like Plot, Effect of Macrolide and Beta-Lactam Combination Therapy
on ECS

Figure 9: Forest-like Plot, Effect of Macrolide and Beta-Lactam Combination Therapy
on 30 Day Mortality
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DISCUSSION

5.1 Discussion of Macrolide and Beta-Lactam Combination Therapy and Early
Clinical Stability

The first objective of this analysis was to determine whether macrolide and
beta-lactam combination therapy usage is appropriate for gold standard
treatment in hospitalized CAP though the assessment of ECS. Overall, macrolide
and beta-lactam combination therapy was not associated with ECS compared to
fluoroquinolone mono-therapy.
When evaluating the effects of macrolide and beta-lactam usage on ECS,
there was a difference in the results depending on the method used to address
CBI. Analysis with logistic regression and propensity score matching, both
addressing measured confounding, showed that macrolide and beta-lactam
therapy was not statistically significantly associated with ECS based on
confidence intervals and p-values, but both odds ratios were less than 1.0
suggesting protection against establishing ECS. This suggests that, according to
these methods for controlling for CBI, macrolide and beta-lactam combination
therapy was associated with decreased likelihood of reaching clinical stability by
day three. Analysis using ADI in instrumental variable analysis addressed
unmeasured confounding and also showed statistically non-significant results.
However the calculated odds ratio suggested that macrolide and beta-lactam
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combination therapy usage was associated with increasing likelihood of
establishing clinical stability on or before day three.
The variation in the odds ratios calculated via the three different methods
suggests there may be unmeasured variables that are important in establishing
ECS that are not being addressed in logistic regression and propensity score
matching. Variables indicated by ADI (a proxy variable) but not actively measured
could be playing an important role in establishing ECS. For example those with
access to primary care physicians and health insurance that cover “sick” visits
may be treated in the outpatient setting for a set time period before the clinician
decides to admit to the hospital, while those with lack of access to the same type
of primary care provider may be going straight to an emergency room for
treatment and be admitted earlier.
There is a difference seen in the results from the methods that analyzed
measured confounding vs the method used to analyze unmeasured confounding,
nevertheless due to confidence intervals, these results are statistically similar.
The confidence intervals from logistic regression and propensity score analysis
were narrower than the confidence interval from instrumental variable analysis.
The confidence interval from instrumental variable analysis was wider because
the instrumental variable, ADI, was a cluster variable. Since the instrumental
variable analysis is essentially calculating a separate model in each block group,
similar to a multilevel model, the overall sample size can affect the smaller
sample seen in each cluster. As the overall sample size is small there isn’t an
equal distribution of macrolide and beta-lactam combination therapy usage and
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ECS in each block group and the sparse data in some of the census block
groups leads to a wider confidence interval. However, even if the sample
analyzed was larger, there is no guarantee that the sample would be evenly
distributed amongst block groups, and thus the confidence interval could
continue to be wide.

5.2 Discussion of Macrolide and Beta-Lactam Combination Therapy and 30 Day
Mortality

Another objective of this analysis was to determine whether macrolide and
beta-lactam combination therapy usage is appropriate for gold standard
treatment in hospitalized community acquired pneumonia though assessment of
30 day mortality. Overall, macrolide and beta-lactam therapy was not associated
with 30 day mortality.
In this analysis there was no difference in the calculated OR’s from the
methods that analyzed measured confounding (logistic regression and propensity
score matching) and from the method used to analyze unmeasured confounding
(instrumental variable analysis). The three odds ratios were statistically similar, in
that each of the the confidence intervals were wide enough to include the OR’s
from the other analytical methods. However the confidence interval for the
instrumental variable analysis was substantially wider than that of the other two
analytical methods. This is due to ADI being a cluster variable and the non-equal
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distribution of macrolide and beta-lactam combination therapy usage and ECS
amongst the census block groups, as discussed previously.
The non-significant OR’s of macrolide and beta-lactam combination
therapy’s effects on 30 day mortality were similar to the results from the meta
analyses (88, 120).
Asadi et al, 2012, initially found that macrolide use was associated with a
statistically significant lower risk of mortality compared with nonmacrolide use,
however there was a large amount of heterogeneity between the studies (88).
When they assessed just the randomized control trials, the reduction in mortality
was no longer apparent. The analysis also found that there was no significant
difference in mortality comparing macrolide and beta-lactam combination therapy
versus fluoroquinolone mono-therapy.
Vardakas et al, 2017, reported that mono-therapy regimens were not
associated with higher mortality when compared with combination therapies,
however the heterogeneity was once again high (120). They found that the
retrospective studies reported higher mortality associated with mono-therapy,
while both prospective studies and RCTs showed no difference in mortality. There
was no difference in mortality between fluoroquinolone mono-therapy and blactam/macrolide combination
The concordance between the results from the analytical methods and the
findings from the meta analyses give credence to the understanding that there is
no difference, with regards to 30 day mortality, between macrolide and betalactam combination therapy and fluoroquinolone mono-therapy.
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5.3 Discussion of Methods for Analyzing Confounding by Indication
Confidence Interval difference
To compare the odds ratios from the various methods of addressing
confounding by indication, the confidence intervals were used as a way to
determine similarities. If one confidence interval included the OR’s from the other
methods, the OR’s were determined to be similar. Although this is a useful
method, there is no statistical significance attached to the results from this
method. There is a lack of analytical methods to compare OR’s from various
methods of calculation. The assumptions made in the analytical methods do not
allow for a simple one-to-one comparison, as is seen in a Wald test.

5.4 Discussion of Macrolide and Beta-Lactam Combination Therapy and
Fluoroquinolone Mono-Therapy

Overall, there was no statistical difference between being given macrolide
and beta-lactam combination therapy and fluoroquinolone mono-therapy with
respect to ECS or 30 day mortality. With these results similar to those seen in
other studies it begs the question, why is macrolide and beta-lactam combination
therapy considered first line treatment compared to fluoroquinolone monotherapy? On one side there are the contraindications and complications
associated with fluoroquinolones, which shouldn’t be ignored. However on the
other side there is an increase in the amount of macrolide resistant S.
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pneumoniae. It is a catch-22 cycle trying to balance side effects with drug
resistance.
There needs be increased discernment in the type of antimicrobial given.
Empiric antimicrobial therapy within the first 6 hours of admission is known to
decrease mortality in patients with CAP. Guidelines also recommend deceleration
of antimicrobial treatment once the pathogen is determined, however few cases
have a defined causal pathogen. In the study population, only 16.5% of patients
had a causal pathogen determined. 85 patients had S. pneumoniae, however
there were 41 different pathogens, both viral and bacterial, identified.
Physicians should have a greater understanding of the causal pathogens
associated with specific risk factors and locations. For example, if a patient has
CAP and is from an area that is experiencing an outbreak, there is a greater
likelihood of Chlamydia pneumoniae or Legionella species being the causative
pathogen, and so caution against macrolide resistant Streptococcus pneumoniae
may not be needed. Rapid diagnostic tests could also be beneficial as the
pathogen could be understood at an earlier point in the course of CAP and the
antimicrobials given could be adjusted accordingly sooner.
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CONCLUSION

6.2.1 Conclusion

In this study population, there is no difference in the likelihood of
establishing ECS according to whether a patient is given macrolide and betalactam combination therapy or fluoroquinolone mono-therapy. The three different
methods used to address CBI (logistic regression, propensity score matching,
instrumental variable analysis) showed overall similar non-significant results,
although instrumental variable analysis, in assessing unmeasured confounding,
found different results from the methods addressing measured confounding.
There is no statistical difference in the likelihood of 30 day mortality between the
antibiotic groups. Logistic regression, propensity score matching, and
instrumental variable analysis all found similar non-significant results. Physicians
need to have a greater understanding of the causal pathogens associated with
specific risk factors and locations. The emergence of macrolide resistant species
of Streptococcus pneumoniae give a reason to cautiously examine the antibiotics
being empirically given, especially as many studies, including this one, suggest
no association between improved clinical outcomes and antibiotic given. There is
a need for better rapid diagnostic tests so that the causal pathogen can be
understood at an earlier time in the clinical course of CAP.
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6.2.2 Strengths
One of the main strengths of this study is that it is a unique data set,
having almost 100% coverage of adults hospitalized with community acquired
pneumonia in Jefferson County, Kentucky. The HAPPI study also had structural
quality control measures (i.e. the entry system would not allow for an age of 500
years to be input, a team of individuals went through the records and assessed
for errors, etc.). The study is comprised of a heterogeneous population with
regards to ethnicity and socioeconomic status. Three different models were used
to evaluate the hypotheses of the study, which led to more informative
conclusions. Furthermore, the exposures were verifiable due to inclusion in
hospital records .

6.2.3 Limitations
Post-hoc power analysis showed analysis was under powered, although
when assessing the outcomes in the study using macrolide use versus non
macrolide use (which was fully powered) similar results were seen. There was a
potential for random error in the entry of information from hospital records,
however this would have been non-differential and so would not have biased
results. There was also no accounting for potential diagnostic differences
between the various radiologists examining the chest x-rays needed for clinical
diagnosis of CAP. However, this would have affected those in both groups, and
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so would have been non-differential. The results from the analysis of the effect of
macrolide and beta-lactam therapy on early clinic stability an 30 day mortality
may not generalizable to the other forms of pneumonia, such as HAP, HCAP,
VAP, etc. Also, there is a question of generalizability of the results when it comes
to other climates, as Jefferson County, Kentucky is situated in the Ohio River
Valley which exposes the patient population to certain environmental exposures
that may affect the pathogenicity of CAP. Intra-personal non-modifiable
differences (i.e. genetics) were not accounted for as they were beyond the scope
of this study.
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APPENDIX I: GLOSSARY

AAFP: American Academy of Family Physicians
ATS: American Thoracic Society
Beta-Lactam: Antimicrobials that are effective against gram positive bacteria and
some gram negative bacteria. They act by inhibiting the synthesis of bacterial
walls.
BMI: Body Mass Index
BTS: British Thoracic Society
BUN: Blood Urea Nitrogen
CAP: Community Acquired Pneumonia
CBI: Confounding by indication
CHF: Congestive heart failure
Confounding: When a variable has been found to influence both the
independent variable (e.g. an antibiotic treatment) and the dependent variable
(e.g. a clinical outcome).
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Confounding by Indication (CBI): A type of confounding that occurs when a
treatment (the primary predictor variable) is selected due to a specific
characteristic (e.g. history of a particular disease, provider medication
preference) and this characteristic also affects the risk of the outcome variable.
COPD: Chronic obstructive pulmonary disease
Community Acquired Pneumonia (CAP): Characterized by acute symptoms
such as dyspnea, cough, fever, or chest pain, it is diagnosed by the presence of
pulmonary infiltrate seen on radiography
CURB-65: Confusion, Urea nitrogen, Respiratory rate, Blood pressure, 65 years
of age and older; Used to predict the need for hospitalization for a patient who
has community acquired pneumonia
CVD: Cerebrovascular disease
DBP: Diastolic blood pressure
ECS: Early Clinical Stability
Early Clinical Stability (ECS): The following criteria are met within 3 days of
admission; improved symptoms of pneumonia (cough and shortness of breath),
lack of fever for at least eight hours, improving leukocytosis (decreased at least
10% from the previous day), and ability to take oral medications
FDA: Federal Drug Administration
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Fluoroquinolone: Antimicrobials that work best against aerobic gram-negative
bacilli. They are direct inhibitors of bacterial DNA synthesis and bind to the
complex of specific enzymes within DNA and thus inhibit progress of the DNA
replication leading to bacterial DNA and bacterial cell death.
HAP: Hospital-acquired pneumonia
HAPPI: Hospitalized Adults with Pneumococcal Pneumonia: Incidence Study
HCAP: Healthcare associated pneumonia
HIV: Human immunodeficiency virus
HR: Heart rate
ICU: Intensive care unit
IDSA: Infectious Diseases Society of America
Instrument: Seemingly random variable that is strongly associated with the
predictor variable under study but not associated with the outcome.
Instrumental Variable Analysis: Makes use of an IV or an instrument to control
for unmeasured variation between confounders.
IV: Intravenous
Logistic Regression: A statistical method for analyzing a dataset in which there
are one or more independent variables that determine an outcome. The outcome
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is measured with a dichotomous variable (in which there are only two possible
outcomes)
Macrolide: Antimicrobials that are used to treat gram positive bacteria, such as
S. pneumoniae, and some gram negative bacteria like H. influenzae. Macrolides
inhibit protein synthesis in bacteria by binding to the 50S ribosomal subunit and
preventing polypeptide elongation and thus protein synthesis.
Pneumonia Severity Index (PSI): Used to predict the need for hospitalization for
a patient who has community acquired pneumonia
Propensity Score: Probability of treatment assignment conditional on observed
baseline characteristics.
PSI: Pneumonia severity index
SBP: Systolic blood pressure
Severe: This variable was created from a score based on the severity criteria
recommended by the ATS/IDSA.
RR: Respiratory rate
VAP: Ventilator-associated pneumonia
30 day mortality: All cause-mortality within 30 days of hospital discharge.
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APPENDIX II: ADDITIONAL TABLES

ECS: Multivariable Logistic Regression, Data-based Method for Assessment
Variable

Validitya

Precisionb Percent Change

Full Model
Macrolide and Beta-Lactam +
Covariates (dem_age + lab_glucose +
smoking.current + hx_ivdruguse +
hx_cirrhosis + lab_hematocrit +
risk_nursinghome + hx_chf + hx_copd
+ exam_hr + severe)

-0.0951

0.0788

remove age

-0.0951

0.0787

0.01%

remove glucose

-0.0964

0.0787

1.31%

remove smoking

-0.0964

0.0787

1.32%

remove IV drug use

-0.0960

0.0788

0.89%

remove cirrhosis

-0.0964

0.0787

1.34%

remove hematocrit

-0.0901

0.0786

5.30%

remove residence in nursing home

-0.0817

0.0784

14.06% +

remove CHF

-0.0914

0.0787

3.92% **

remove COPD

-0.0811

0.0785

14.69% **+

remove HR

-0.1072

0.0785

12.74% **+

remove severe

-0.1189

0.0782

24.95% **+

a, Beta coefficient for the effect of macrolide + beta-lactam usage on ECS
b, Standard error
+, changed the beta coefficient of macrolide + beta-lactam more than 10%
**, statistically significant in full model so will be included in final model
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ECS: Multivariable Logistic Regression, Data-based Method for Assessment (continued)
Variable

Validitya

Precisionb Percent Change

Remove dem_age
Macrolide and Beta-Lactam +
Covariates (lab_glucose +
smoking.current + hx_ivdruguse +
hx_cirrhosis + lab_hematocrit +
risk_nursinghome + hx_chf + hx_copd
+ exam_hr + severe)

-0.0951

0.0787

remove glucose

-0.0964

0.0786

1.33%

remove smoking

-0.0969

0.0787

1.88%

remove IV drug use

-0.0961

0.0787

1.06%

remove cirrhosis

-0.0964

0.0787

1.34%

remove hematocrit

-0.0901

0.0786

5.24%

remove residence in nursing home

-0.0812

0.0783

14.58% +

remove CHF

-0.0907

0.0786

4.62% **

remove COPD

-0.0790

0.0785

16.90% **+

remove HR

-0.1098

0.0784

15.43% **+

remove severe

-0.1176

0.0782

23.67% **+

Macrolide and Beta-Lactam +
Covariates (smoking.current +
hx_ivdruguse + hx_cirrhosis +
lab_hematocrit + risk_nursinghome +
hx_chf + hx_copd + exam_hr +
severe)

-0.0964

0.0786

remove smoking

-0.0982

0.0786

1.92%

remove IV drug use

-0.0973

0.0786

0.95%

remove cirrhosis

-0.0977

0.0786

1.34%

remove hematocrit

-0.0914

0.0785

5.18%

Remove dem_age + lab_glucose

a, Beta coefficient for the effect of macrolide + beta-lactam usage on ECS
b, Standard error
+, changed the beta coefficient of macrolide + beta-lactam more than 10%
**, statistically significant in full model so will be included in final model
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ECS: Multivariable Logistic Regression, Data-based Method for Assessment (continued)
Variable

Validitya

remove residence in nursing home

-0.0825

0.0782

14.41% +

remove CHF

-0.0929

0.0785

3.56% **

remove COPD

-0.0813

0.0783

15.68% **+

remove HR

-0.1127

0.0783

16.99% **+

remove severe

-0.1206

0.0781

25.20% **+

Macrolide and Beta-Lactam +
Covariates (hx_ivdruguse +
hx_cirrhosis + lab_hematocrit +
risk_nursinghome + hx_chf + hx_copd
+ exam_hr + severe)

-0.0982

0.0786

remove IV drug use

-0.0996

0.0785

1.42%

remove cirrhosis

-0.0996

0.0785

1.39%

remove hematocrit

-0.0933

0.0784

5.02%

remove residence in nursing home

-0.0842

0.0781

14.32% +

remove CHF

-0.0940

0.0784

4.27% **

remove COPD

-0.0849

0.0783

13.51% **+

remove HR

-0.1159

0.0782

18.00% **+

remove severe

-0.1214

0.0780

23.58% **+

Precisionb Percent Change

Remove dem_age + lab_glucose +
smoking.current

a, Beta coefficient for the effect of macrolide + beta-lactam usage on ECS
b, Standard error
+, changed the beta coefficient of macrolide + beta-lactam more than 10%
**, statistically significant in full model so will be included in final model
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ECS: Multivariable Logistic Regression, Data-based Method for Assessment (continued)
Variable

Validitya

Precisionb Percent Change

Remove dem_age + lab_glucose +
smoking.current + hx_ivdruguse
Macrolide and Beta-Lactam +
Covariates (hx_cirrhosis +
lab_hematocrit + risk_nursinghome +
hx_chf + hx_copd + exam_hr +
severe)

-0.0996

0.0785

remove cirrhosis

-0.1011

0.0785

1.54%

remove hematocrit

-0.0947

0.0784

4.96%

remove residence in nursing home

-0.0855

0.0781

14.18% +

remove CHF

-0.0953

0.0784

4.35% **

remove COPD

-0.0860

0.0782

13.64% **+

remove HR

-0.1183

0.0782

18.81% **+

remove severe

-0.1234

0.0780

23.85% **+

Macrolide and Beta-Lactam +
Covariates (lab_hematocrit +
risk_nursinghome + hx_chf + hx_copd
+ exam_hr + severe)

-0.1011

0.0785

remove hematocrit

-0.0962

0.0783

remove residence in nursing home

-0.0871

0.0780

13.93% +

remove CHF

-0.0968

0.0784

4.32% **

remove COPD

-0.0876

0.0782

13.41% **+

remove HR

-0.1199

0.0781

18.59% **+

remove severe

-0.1251

0.0779

23.71% **+

Remove dem_age + lab_glucose +
smoking.current + hx_ivdruguse +
hx_cirrhosis

a, Beta coefficient for the effect of macrolide + beta-lactam usage on ECS
b, Standard error
+, changed the beta coefficient of macrolide + beta-lactam more than 10%
**, statistically significant in full model so will be included in final model
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4.87%

ECS: Multivariable Logistic Regression, Data-based Method for Assessment (continued)
Variable

Validitya

Precisionb Percent Change

Remove dem_age + lab_glucose +
smoking.current + hx_ivdruguse +
hx_cirrhosis + lab_hematocrit
Macrolide and Beta-Lactam +
Covariates (risk_nursinghome +
hx_chf + hx_copd + exam_hr +
severe)

-0.0962

0.0783

remove residence in nursing home

-0.0830

0.0779

13.73% **+

remove CHF

-0.0925

0.0782

3.85% **

remove COPD

-0.0807

0.0780

16.16% **+

remove HR

-0.1141

0.0780

18.53% **+

remove severe

-0.1235

0.0778

28.32% +

a, Beta coefficient for the effect of macrolide + beta-lactam usage on ECS
b, Standard error
+, changed the beta coefficient of macrolide + beta-lactam more than 10%
**, statistically significant in full model so will be included in final model

30 Day Mortality: Multivariable Logistic Regression, Data-based Method for Assessment
Variable

Percent Change

Validitya

Precisionb

Macrolide and Beta-Lactam +
Covariates (smoking.current +
hx_copd + hx_chf +
risk_nursinghome + hx_cirrhosis +
lab_glucose + hx_ivdruguse +
lab_hematocrit + exam_hr + severe +
dem_age)

-0.0734

0.7426

remove smoking

-0.0741

0.1495

0.97%

remove COPD

-0.0767

0.1494

4.59%

Full Model

a, Beta coefficient for the effect of macrolide + beta-lactam usage on 30 Day Mortality
b, Standard error
+, changed the beta coefficient of macrolide + beta-lactam more than 10%
**, statistically significant in full model so will be included in final model

!96

30 Day Mortality: Multivariable Logistic Regression, Data-based Method for Assessment
(continued)
Variable

Validitya

Precisionb

Percent Change

remove CHF

-0.0769

0.1494

4.78%

remove residence in nursing home

-0.0962

0.1483

remove cirrhosis

-0.0679

0.1493

remove glucose

-0.0581

0.1491

20.86% +

remove IV drug use

-0.0668

0.1494

8.91% **

remove hematocrit

-0.0361

0.1487

50.83% **+

remove HR

-0.0500

0.1484

31.89% **+

remove severe

-0.0219

0.1480

70.18% **+

remove age

-0.0822

0.0822

12.11% **+

Macrolide and Beta-Lactam +
Covariates (hx_copd + hx_chf +
risk_nursinghome + hx_cirrhosis +
lab_glucose + hx_ivdruguse +
lab_hematocrit + exam_hr + severe +
dem_age)

-0.0741

0.1495

remove COPD

-0.0769

0.1494

3.83%

remove CHF

-0.0779

0.1494

5.24%

remove residence in nursing home

-0.0973

0.1482

remove cirrhosis

-0.0686

0.1493

remove glucose

-0.0588

0.1491

20.60% +

remove IV drug use

-0.0671

0.1493

9.38% **

remove hematocrit

-0.0371

0.1486

49.93% **+

remove HR

-0.0505

0.1484

31.86% **+

31.14% +
7.44%

Remove smoking.current

31.35% +
7.43%

a, Beta coefficient for the effect of macrolide + beta-lactam usage on 30 Day Mortality
b, Standard error
+, changed the beta coefficient of macrolide + beta-lactam more than 10%
**, statistically significant in full model so will be included in final model
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30 Day Mortality: Multivariable Logistic Regression, Data-based Method for Assessment
(continued)
Variable

Validitya

Precisionb

remove severe

-0.0228

0.1480

69.25% **+

remove age

-0.0921

0.1476

24.34% **+

Macrolide and Beta-Lactam +
Covariates (hx_chf +
risk_nursinghome + hx_cirrhosis +
lab_glucose + hx_ivdruguse +
lab_hematocrit + exam_hr + severe +
dem_age)

-0.0769

0.1494

remove CHF

-0.0823

0.1492

remove residence in nursing home

-0.1001

0.1481

remove cirrhosis

-0.0713

0.1492

remove glucose

-0.0622

0.1490

19.11% +

remove IV drug use

-0.0695

0.1492

9.64% **

remove hematocrit

-0.0375

0.1484

51.27% **+

remove HR

-0.0550

0.1483

28.43% **+

remove severe

-0.0265

0.1479

65.55% **+

remove age

-0.0968

0.1474

25.88% **+

Macrolide and Beta-Lactam +
Covariates (risk_nursinghome +
hx_cirrhosis + lab_glucose +
hx_ivdruguse + lab_hematocrit +
exam_hr + severe + dem_age)

-0.0823

0.1492

remove residence in nursing home

-0.1058

0.1479

remove cirrhosis

-0.0764

0.1490

Percent Change

Remove smoking.current + hx_copd

6.99%
30.22% +
7.23%

Remove smoking.current + hx_copd +
hx_chf

28.64% +
7.12%

a, Beta coefficient for the effect of macrolide + beta-lactam usage on 30 Day Mortality
b, Standard error
+, changed the beta coefficient of macrolide + beta-lactam more than 10%
**, statistically significant in full model so will be included in final model
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30 Day Mortality: Multivariable Logistic Regression, Data-based Method for Assessment
(continued)
Variable

Validitya

Precisionb

remove glucose

-0.0670

0.1489

18.51% +

remove IV drug use

-0.0748

0.1490

9.14% **

remove hematocrit

-0.0421

0.1483

48.87% **+

remove HR

-0.0602

0.1482

26.82% **+

remove severe

-0.0330

0.1477

59.83% **+

remove age

-0.1089

0.1471

32.42% **+

Macrolide and Beta-Lactam +
Covariates (risk_nursinghome +
lab_glucose + hx_ivdruguse +
lab_hematocrit + exam_hr + severe +
dem_age)

-0.0764

0.1490

remove residence in nursing home

-0.0996

0.1477

30.36% +

remove glucose

-0.0614

0.1487

19.70% +

remove IV drug use

-0.0686

0.1489

10.23% **+

remove hematocrit

-0.0375

0.1481

50.96% **+

remove HR

-0.0543

0.1480

28.90% **+

remove severe

-0.0258

0.1475

66.19% **+

remove age

-0.1039

0.1469

35.94% **+

Percent Change

Remove smoking.current + hx_copd +
hx_chf + hx_cirrhosis

a, Beta coefficient for the effect of macrolide + beta-lactam usage on 30 Day Mortality
b, Standard error
+, changed the beta coefficient of macrolide + beta-lactam more than 10%
**, statistically significant in full model so will be included in final model
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